Comprehensive Physiology Wiley Online Library
For Librarians For Authors Editors About

Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus

Maggie S. Burhans, Derek K. Hagman, Jessica N. Kuzma, Kelsey A. Schmidt, Mario Kratz

10.1002/cphy.c170040

Source: Volume 9, Issue 1, January 2019

Published online: December 2018

Full Article on Wiley Online Library



ABSTRACT

The objective of this comprehensive review is to summarize and discuss the available evidence of how adipose tissue inflammation affects insulin sensitivity and glucose tolerance. Low‐grade, chronic adipose tissue inflammation is characterized by infiltration of macrophages and other immune cell populations into adipose tissue, and a shift toward more proinflammatory subtypes of leukocytes. The infiltration of proinflammatory cells in adipose tissue is associated with an increased production of key chemokines such as C‐C motif chemokine ligand 2, proinflammatory cytokines including tumor necrosis factor α and interleukins 1β and 6 as well as reduced expression of the key insulin‐sensitizing adipokine, adiponectin. In both rodent models and humans, adipose tissue inflammation is consistently associated with excess fat mass and insulin resistance. In humans, associations with insulin resistance are stronger and more consistent for inflammation in visceral as opposed to subcutaneous fat. Further, genetic alterations in mouse models of obesity that reduce adipose tissue inflammation are—almost without exception—associated with improved insulin sensitivity. However, a dissociation between adipose tissue inflammation and insulin resistance can be observed in very few rodent models of obesity as well as in humans following bariatric surgery‐ or low‐calorie‐diet‐induced weight loss, illustrating that the etiology of insulin resistance is multifactorial. Taken together, adipose tissue inflammation is a key factor in the development of insulin resistance and type 2 diabetes in obesity, along with other factors that likely include inflammation and fat accumulation in other metabolically active tissues. © 2019 American Physiological Society. Compr Physiol 9:1‐58, 2019.

Comprehensive Physiology offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images


Figure 1. Figure 1. Associations between obesity, insulin resistance, and adipose tissue inflammation. Obesity is associated with both insulin resistance and adipose tissue inflammation in humans and rodent models. Adipose tissue inflammation and insulin resistance are also associated, but the direction of causality is controversial. This review will explore each of these relationships, highlighting evidence generated from studies conducted in both humans and rodents.
Figure 2. Figure 2. Causes of and health risks associated with obesity. Several factors contribute to the development of obesity; these factors may have an environmental, biological, or genetic basis. Obesity subsequently increases the risk for the development of many diseases and disorders, including CVD, T2DM, and cancer, three of the top ten killers of adults in the United States. Abbreviations: SES, socioeconomic status; PCOS, polycystic ovary syndrome; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus; NAFLD, nonalcoholic fatty liver disease; GERD, gastroesophageal reflux disease.
Figure 3. Figure 3. Insulin sensitivity, pancreatic β‐cell function, and glucose effectiveness in the regulation of glucose homeostasis. Glucose tolerance, that is, the body's ability to maintain glucose within a relatively narrow homeostatic range, is regulated by three key factors: insulin sensitivity, pancreatic β‐cell function, and glucose effectiveness (A) (38,215,420). Insulin sensitivity is the responsiveness of liver and extrahepatic tissues, such as skeletal muscle and adipose tissue, to insulin (215). There are a number of physiological and pathophysiological mechanisms that affect insulin sensitivity, as we will discuss throughout this article. In healthy, glucose tolerant individuals, as insulin sensitivity declines, the pancreatic β‐cell will compensate by producing and secreting more insulin (B) (217). Only when the β‐cell is unable to fully compensate for a given degree of insulin resistance will glucose intolerance ensue (217). This phenomenon, commonly called β‐cell dysfunction, is a critical component of glucose homeostasis (217). In fact, in healthy, glucose tolerant individuals, the product of insulin sensitivity and pancreatic β‐cell function, the disposition index, is constant as insulin sensitivity changes due to physiologic or pathophysiologic events (217). Put more simply, highly insulin‐sensitive individuals release little insulin in response to glucose stimulation, simply because more is not needed and would, in fact, be harmful, while less‐insulin‐sensitive individuals secrete more insulin to maintain normal glucose homeostasis. It is only when insulin production and secretion cannot fully compensate for insulin resistance that the disposition index declines and glucose intolerance and eventually T2DM ensues (217). The third key factor contributing to glucose homeostasis is glucose effectiveness, the ability of glucose to drive its own disposal and inhibit endogenous gluconeogenesis, in a manner independent of insulin (38,420). Even though glucose effectiveness clearly exhibits substantial inter‐individual variability (420), and reduced glucose effectiveness is as much a risk factor for T2DM as reduced insulin sensitivity (291), little is known about factors affecting glucose effectiveness. Glucose effectiveness is therefore often overlooked in studies of glucose homeostasis (101). Figure 3b reproduced from Kahn et al. (216), with permission.
Figure 4. Figure 4. Obesity is associated with the development of insulin resistance. The association between excess adiposity and insulin resistance is well established; however, there are exceptions to the relationship wherein obese individuals may be insulin sensitive and individuals with a deficit of adipose tissue, as in lipodystrophy, may be severely insulin resistant.
Figure 5. Figure 5. Variation in adiposity and insulin resistance among inbred strains of mice. Males and females of more than 100 inbred strains of mice were fed a high‐sucrose high‐fat diet for 8 weeks. Adiposity and systemic insulin resistance were highly variable in response to this diet. (A) HOMA‐IR was determined in males and females. HOMA‐IR was correlated with total body fat percentage (B and F) and with mesenteric (C and G), gonadal (D and H), and retroperitoneal (E and I) adipose depots of both male (B‐E) and female (F‐I) mice. The substantial variability in insulin resistance at any given level of adiposity can be appreciated in panels B to I. These data reveal that there is substantial genetic control over these metabolic phenotypes and that total adiposity may not be the primary factor driving insulin resistance. Reproduced from Parks et al. (371), with permission.
Figure 6. Figure 6. Insulin sensitivity and adiposity are negatively associated in humans. Insulin sensitivity was determined by glucose infusion rate from euglycemic‐hyperinsulinemic clamps and plotted against adiposity as estimated by BMI. These data highlight the variability in insulin sensitivity at any given BMI. Although an inverse association between BMI and insulin sensitivity generally applies on a population level, there is large variability in insulin sensitivity at any given BMI, particularly at among the overweight and obese BMI categories (>25 kg/m2). Of note, there are obese individuals who maintain a level of insulin sensitivity equivalent to those with BMI around 25 kg/m2. These individuals may be referred to as “metabolically healthy obese (MHO)” and comprise approximately 10% to 30% of the obese population. These individuals remain free from the metabolic syndrome and glucose intolerance that would be expected based on their BMI. Reproduced from Klöting et al. (238).
Figure 7. Figure 7. Type 2 diabetes is an aging‐associated disease. The prevalence of diabetes increases with age and is substantially increased in the 65 and older population as compared to the 45‐ to 64‐year‐old population (65).
Figure 8. Figure 8. Metabolic characterization of obesity, metabolically healthy obesity (MHO), and lipodystrophy. Metabolically functional, healthy adipose tissue may be a key determinant of overall metabolic health. Although all obese individuals are characterized by excess adiposity, not all obese individuals develop metabolic dysfunction. An estimated 10% to 30% of the obese population may be metabolically healthy and exhibit reduced ectopic fat accumulation and are more insulin sensitive compared to metabolically unhealthy obese individuals (44,45). Lipodystrophy is characterized by reduced adiposity but is accompanied by metabolic dysfunction including ectopic fat deposition and severe insulin resistance (140). The metabolic differences among obese, MHO, and lipodystrophic populations reveal that total adiposity is not likely the major determinant of metabolic health but rather that metabolically functional adipose tissue that maintains insulin sensitivity is a major contributor to whole‐body metabolic health.
Figure 9. Figure 9. Adipose tissue inflammation may be a driving factor in the development of systemic insulin resistance (IR). Chronic, low‐grade adipose tissue inflammation is associated with the development of systemic IR in obesity. There are several mechanisms through which adipose tissue inflammation may contribute to IR: (A) the secretion of cytokines by obese adipose tissue directly contributes to systemic inflammation which is associated with IR; (B) adipose tissue‐derived cytokines also impair local adipocyte insulin sensitivity which leads to increased lipolysis and secretion of free fatty acids; and (C) inflamed adipose tissue is also associated with reduced secretion of the insulin‐sensitizing adipokine adiponectin. Adiponectin receptors contain intrinsic ceramidase activity, and reduced adiponectin as well as increased proinflammatory cytokine signaling may lead to increased levels of ceramides, which are associated with adipose tissue inflammation and insulin resistance; (D) elevated circulating free fatty acids and reduced adiponectin are associated with increased ectopic fat deposition. Hepatic and skeletal muscle fat accumulation are associated with impaired insulin signaling and systemic IR.
Figure 10. Figure 10. Obesity is associated with adipose tissue inflammation. The development of chronic, low‐grade adipose tissue inflammation is common in obesity.
Figure 11. Figure 11. Insulin resistance and adipose tissue inflammation are strongly associated. Although insulin resistance and adipose tissue inflammation generally characterize obese adipose tissue, the direction of causality has not been conclusively determined.
Figure 12. Figure 12. Key functions of macrophages in adipose tissue physiology. Leukocytes infiltrating adipose tissue, particularly macrophages, play key roles in processes that allow growth of adipose tissue in the context of chronic caloric excess. These include the breakdown of extracellular matrix proteins as cells expand and to create room for new adipocytes, and laying down new extracellular matrix, processes that are collectively known as “tissue remodeling” (A). Macrophages also play a critical role in the formation of new blood vessels as the tissue expands, that is, angiogenesis (B). The activation of inflammatory pathways in adipocytes and immune cells (C) also may play an important physiological role, because the induction of insulin resistance in adipocytes (D) may serve to limit excessive hypertrophy of these cells, which is known to trigger cell death. Macrophages are also able to intermittently store lipid (E), which could become important whenever the lipid‐storage capacity of adipocytes is (temporarily) restricted. And lastly, macrophages play a key role in the removal of cellular debris from necrotic or apoptotic adipocytes or senescent cells (F).
Figure 13. Figure 13. Adipose tissue inflammation, ectopic fat deposition, and insulin resistance in obesity. In the context of chronic caloric excess, adipose tissue is challenged to store excess calories in the form of TG. This requires either the differentiation of preadipocytes to mature adipocytes (hyperplasia) or hypertrophy of existing adipocytes. Currently available evidence suggests that the ability of adipose tissue, particularly subcutaneous adipose tissue, to expand in a healthy fashion is reliant primarily upon hyperplasia, which prevents excessive adipocyte hypertrophy. This is one key differentiating factor between obese individuals that remain relatively insulin sensitive (upper panel) from those that become insulin resistant (lower panel). Larger adipocytes are more susceptible to cell death and are more strongly associated with immune cell infiltration and activation of proinflammatory pathways within adipocytes and infiltrating leukocytes. Together these processes promote insulin resistance within the expanded adipose tissue. Inflammation and insulin resistance in adipose tissue are major contributors to low‐grade chronic systemic inflammation, hypoadiponectinemia, and an elevated flux of free fatty acids (FFA) to the liver, muscle, and pancreas, eventually contributing to excessive ectopic fat storage in these organs. Elevated concentrations of TG in liver and muscle are considered a major contributor to insulin resistance in these organs, and TG stored in the pancreas may contribute to pancreatic β‐cell dysfunction, that is, the inability of the β‐cell to fully compensate for insulin resistance. The importance of adipose tissue inflammation in driving systemic insulin resistance relative to the other, interlinked factors outlined here is currently unclear, particularly in humans.


Figure 1. Associations between obesity, insulin resistance, and adipose tissue inflammation. Obesity is associated with both insulin resistance and adipose tissue inflammation in humans and rodent models. Adipose tissue inflammation and insulin resistance are also associated, but the direction of causality is controversial. This review will explore each of these relationships, highlighting evidence generated from studies conducted in both humans and rodents.


Figure 2. Causes of and health risks associated with obesity. Several factors contribute to the development of obesity; these factors may have an environmental, biological, or genetic basis. Obesity subsequently increases the risk for the development of many diseases and disorders, including CVD, T2DM, and cancer, three of the top ten killers of adults in the United States. Abbreviations: SES, socioeconomic status; PCOS, polycystic ovary syndrome; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus; NAFLD, nonalcoholic fatty liver disease; GERD, gastroesophageal reflux disease.


Figure 3. Insulin sensitivity, pancreatic β‐cell function, and glucose effectiveness in the regulation of glucose homeostasis. Glucose tolerance, that is, the body's ability to maintain glucose within a relatively narrow homeostatic range, is regulated by three key factors: insulin sensitivity, pancreatic β‐cell function, and glucose effectiveness (A) (38,215,420). Insulin sensitivity is the responsiveness of liver and extrahepatic tissues, such as skeletal muscle and adipose tissue, to insulin (215). There are a number of physiological and pathophysiological mechanisms that affect insulin sensitivity, as we will discuss throughout this article. In healthy, glucose tolerant individuals, as insulin sensitivity declines, the pancreatic β‐cell will compensate by producing and secreting more insulin (B) (217). Only when the β‐cell is unable to fully compensate for a given degree of insulin resistance will glucose intolerance ensue (217). This phenomenon, commonly called β‐cell dysfunction, is a critical component of glucose homeostasis (217). In fact, in healthy, glucose tolerant individuals, the product of insulin sensitivity and pancreatic β‐cell function, the disposition index, is constant as insulin sensitivity changes due to physiologic or pathophysiologic events (217). Put more simply, highly insulin‐sensitive individuals release little insulin in response to glucose stimulation, simply because more is not needed and would, in fact, be harmful, while less‐insulin‐sensitive individuals secrete more insulin to maintain normal glucose homeostasis. It is only when insulin production and secretion cannot fully compensate for insulin resistance that the disposition index declines and glucose intolerance and eventually T2DM ensues (217). The third key factor contributing to glucose homeostasis is glucose effectiveness, the ability of glucose to drive its own disposal and inhibit endogenous gluconeogenesis, in a manner independent of insulin (38,420). Even though glucose effectiveness clearly exhibits substantial inter‐individual variability (420), and reduced glucose effectiveness is as much a risk factor for T2DM as reduced insulin sensitivity (291), little is known about factors affecting glucose effectiveness. Glucose effectiveness is therefore often overlooked in studies of glucose homeostasis (101). Figure 3b reproduced from Kahn et al. (216), with permission.


Figure 4. Obesity is associated with the development of insulin resistance. The association between excess adiposity and insulin resistance is well established; however, there are exceptions to the relationship wherein obese individuals may be insulin sensitive and individuals with a deficit of adipose tissue, as in lipodystrophy, may be severely insulin resistant.


Figure 5. Variation in adiposity and insulin resistance among inbred strains of mice. Males and females of more than 100 inbred strains of mice were fed a high‐sucrose high‐fat diet for 8 weeks. Adiposity and systemic insulin resistance were highly variable in response to this diet. (A) HOMA‐IR was determined in males and females. HOMA‐IR was correlated with total body fat percentage (B and F) and with mesenteric (C and G), gonadal (D and H), and retroperitoneal (E and I) adipose depots of both male (B‐E) and female (F‐I) mice. The substantial variability in insulin resistance at any given level of adiposity can be appreciated in panels B to I. These data reveal that there is substantial genetic control over these metabolic phenotypes and that total adiposity may not be the primary factor driving insulin resistance. Reproduced from Parks et al. (371), with permission.


Figure 6. Insulin sensitivity and adiposity are negatively associated in humans. Insulin sensitivity was determined by glucose infusion rate from euglycemic‐hyperinsulinemic clamps and plotted against adiposity as estimated by BMI. These data highlight the variability in insulin sensitivity at any given BMI. Although an inverse association between BMI and insulin sensitivity generally applies on a population level, there is large variability in insulin sensitivity at any given BMI, particularly at among the overweight and obese BMI categories (>25 kg/m2). Of note, there are obese individuals who maintain a level of insulin sensitivity equivalent to those with BMI around 25 kg/m2. These individuals may be referred to as “metabolically healthy obese (MHO)” and comprise approximately 10% to 30% of the obese population. These individuals remain free from the metabolic syndrome and glucose intolerance that would be expected based on their BMI. Reproduced from Klöting et al. (238).


Figure 7. Type 2 diabetes is an aging‐associated disease. The prevalence of diabetes increases with age and is substantially increased in the 65 and older population as compared to the 45‐ to 64‐year‐old population (65).


Figure 8. Metabolic characterization of obesity, metabolically healthy obesity (MHO), and lipodystrophy. Metabolically functional, healthy adipose tissue may be a key determinant of overall metabolic health. Although all obese individuals are characterized by excess adiposity, not all obese individuals develop metabolic dysfunction. An estimated 10% to 30% of the obese population may be metabolically healthy and exhibit reduced ectopic fat accumulation and are more insulin sensitive compared to metabolically unhealthy obese individuals (44,45). Lipodystrophy is characterized by reduced adiposity but is accompanied by metabolic dysfunction including ectopic fat deposition and severe insulin resistance (140). The metabolic differences among obese, MHO, and lipodystrophic populations reveal that total adiposity is not likely the major determinant of metabolic health but rather that metabolically functional adipose tissue that maintains insulin sensitivity is a major contributor to whole‐body metabolic health.


Figure 9. Adipose tissue inflammation may be a driving factor in the development of systemic insulin resistance (IR). Chronic, low‐grade adipose tissue inflammation is associated with the development of systemic IR in obesity. There are several mechanisms through which adipose tissue inflammation may contribute to IR: (A) the secretion of cytokines by obese adipose tissue directly contributes to systemic inflammation which is associated with IR; (B) adipose tissue‐derived cytokines also impair local adipocyte insulin sensitivity which leads to increased lipolysis and secretion of free fatty acids; and (C) inflamed adipose tissue is also associated with reduced secretion of the insulin‐sensitizing adipokine adiponectin. Adiponectin receptors contain intrinsic ceramidase activity, and reduced adiponectin as well as increased proinflammatory cytokine signaling may lead to increased levels of ceramides, which are associated with adipose tissue inflammation and insulin resistance; (D) elevated circulating free fatty acids and reduced adiponectin are associated with increased ectopic fat deposition. Hepatic and skeletal muscle fat accumulation are associated with impaired insulin signaling and systemic IR.


Figure 10. Obesity is associated with adipose tissue inflammation. The development of chronic, low‐grade adipose tissue inflammation is common in obesity.


Figure 11. Insulin resistance and adipose tissue inflammation are strongly associated. Although insulin resistance and adipose tissue inflammation generally characterize obese adipose tissue, the direction of causality has not been conclusively determined.


Figure 12. Key functions of macrophages in adipose tissue physiology. Leukocytes infiltrating adipose tissue, particularly macrophages, play key roles in processes that allow growth of adipose tissue in the context of chronic caloric excess. These include the breakdown of extracellular matrix proteins as cells expand and to create room for new adipocytes, and laying down new extracellular matrix, processes that are collectively known as “tissue remodeling” (A). Macrophages also play a critical role in the formation of new blood vessels as the tissue expands, that is, angiogenesis (B). The activation of inflammatory pathways in adipocytes and immune cells (C) also may play an important physiological role, because the induction of insulin resistance in adipocytes (D) may serve to limit excessive hypertrophy of these cells, which is known to trigger cell death. Macrophages are also able to intermittently store lipid (E), which could become important whenever the lipid‐storage capacity of adipocytes is (temporarily) restricted. And lastly, macrophages play a key role in the removal of cellular debris from necrotic or apoptotic adipocytes or senescent cells (F).


Figure 13. Adipose tissue inflammation, ectopic fat deposition, and insulin resistance in obesity. In the context of chronic caloric excess, adipose tissue is challenged to store excess calories in the form of TG. This requires either the differentiation of preadipocytes to mature adipocytes (hyperplasia) or hypertrophy of existing adipocytes. Currently available evidence suggests that the ability of adipose tissue, particularly subcutaneous adipose tissue, to expand in a healthy fashion is reliant primarily upon hyperplasia, which prevents excessive adipocyte hypertrophy. This is one key differentiating factor between obese individuals that remain relatively insulin sensitive (upper panel) from those that become insulin resistant (lower panel). Larger adipocytes are more susceptible to cell death and are more strongly associated with immune cell infiltration and activation of proinflammatory pathways within adipocytes and infiltrating leukocytes. Together these processes promote insulin resistance within the expanded adipose tissue. Inflammation and insulin resistance in adipose tissue are major contributors to low‐grade chronic systemic inflammation, hypoadiponectinemia, and an elevated flux of free fatty acids (FFA) to the liver, muscle, and pancreas, eventually contributing to excessive ectopic fat storage in these organs. Elevated concentrations of TG in liver and muscle are considered a major contributor to insulin resistance in these organs, and TG stored in the pancreas may contribute to pancreatic β‐cell dysfunction, that is, the inability of the β‐cell to fully compensate for insulin resistance. The importance of adipose tissue inflammation in driving systemic insulin resistance relative to the other, interlinked factors outlined here is currently unclear, particularly in humans.
References
 1.Abate N, Garg A, Peshock RM, Stray‐Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 96: 88‐98, 1995.
 2.Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, Isenovic ER. Resistin: An inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des 20: 4961‐4969, 2014.
 3.Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: A meta‐analysis of prospective cohort studies. Diabetes Res Clin Pract 89: 309‐319, 2010.
 4.Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 172: 899‐905, 2005.
 5.Adamson SE, Griffiths R, Moravec R, Senthivinayagam S, Montgomery G, Chen W, Han J, Sharma PR, Mullins GR, Gorski SA, Cooper JA, Kadl A, Enfield K, Braciale TJ, Harris TE, Leitinger N. Disabled homolog 2 controls macrophage phenotypic polarization and adipose tissue inflammation. J Clin Invest 126: 1311‐1322, 2016.
 6.Aghamohammadzadeh R, Greenstein AS, Yadav R, Jeziorska M, Hama S, Soltani F, Pemberton PW, Ammori B, Malik RA, Soran H, Heagerty AM. Effects of bariatric surgery on human small artery function: Evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity. J Am Coll Cardiol 62: 128‐135, 2013.
 7.Aguilar‐Salinas CA, Garcia EG, Robles L, Riano D, Ruiz‐Gomez DG, Garcia‐Ulloa AC, Melgarejo MA, Zamora M, Guillen‐Pineda LE, Mehta R, Canizales‐Quinteros S, Tusie Luna MT, Gomez‐Perez FJ. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93: 4075‐4079, 2008.
 8.Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol (Baltimore, Md) 22: 1023‐1031, 2008.
 9.Ahl S, Guenther M, Zhao S, James R, Marks J, Szabo A, Kidambi S. Adiponectin levels differentiate metabolically healthy vs unhealthy among obese and nonobese white individuals. J Clin Endocrinol Metab 100: 4172‐4180, 2015.
 10.Ahren B, Pacini G. Age‐related reduction in glucose elimination is accompanied by reduced glucose effectiveness and increased hepatic insulin extraction in man. J Clin Endocrinol Metab 83: 3350‐3356, 1998.
 11.Ahren B, Pacini G. Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose‐intolerant mice. Am J Physiol Endocrinol Metab 283: E738‐E744, 2002.
 12.Albert JS, Yerges‐Armstrong LM, Horenstein RB, Pollin TI, Sreenivasan UT, Chai S, Blaner WS, Snitker S, O'Connell JR, Gong DW, Breyer RJ, III, Ryan AS, McLenithan JC, Shuldiner AR, Sztalryd C, Damcott CM. Null mutation in hormone‐sensitive lipase gene and risk of type 2 diabetes. New Engl J Med 370: 2307‐2315, 2014.
 13.Alderete TL, Sattler FR, Richey JM, Allayee H, Mittelman SD, Sheng X, Tucci J, Gyllenhammer LE, Grant EG, Goran MI. Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics. Obesity (Silver Spring) 23: 543‐551, 2015.
 14.Aleman JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, Giri DD, Zhou XK, Pollak MN, Hudis CA, Breslow JL, Holt PR, Dannenberg AJ. Effects of rapid weight loss on systemic and adipose tissue inflammation and metabolism in obese postmenopausal women. J Endocr Soc 1: 625‐637, 2017.
 15.Alligier M, Meugnier E, Debard C, Lambert‐Porcheron S, Chanseaume E, Sothier M, Loizon E, Hssain AA, Brozek J, Scoazec JY, Morio B, Vidal H, Laville M. Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. J Clin Endocrinol Metab 97: E183‐E192, 2012.
 16.Altintas MM, Azad A, Nayer B, Contreras G, Zaias J, Faul C, Reiser J, Nayer A. Mast cells, macrophages and crown‐like structures distinguish subcutaneous from visceral fat in mice. J Lipid Res 52: 480‐488, 2011.
 17.Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez‐Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Rautonen N, Sansonetti PJ, Burcelin R. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: Molecular mechanisms and probiotic treatment. EMBO Mol Med 3: 559‐572, 2011.
 18.Amati F, Dube JJ, Coen PM, Stefanovic‐Racic M, Toledo FG, Goodpaster BH. Physical inactivity and obesity underlie the insulin resistance of aging. Diabetes Care 32: 1547‐1549, 2009.
 19.American Diabetes Association. The cost of diabetes. http://www.diabetes.org/advocacy/news‐events/cost‐of‐diabetes.html. Accessed on August 31, 2017.
 20.Anderson EK, Gutierrez DA, Kennedy A, Hasty AH. Weight cycling increases T‐cell accumulation in adipose tissue and impairs systemic glucose tolerance. Diabetes 62: 3180‐3188, 2013.
 21.Anstee QM, Goldin RD. Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1‐16, 2006.
 22.Aouadi M, Tencerova M, Vangala P, Yawe JC, Nicoloro SM, Amano SU, Cohen JL, Czech MP. Gene silencing in adipose tissue macrophages regulates whole‐body metabolism in obese mice. Proc Natl Acad Sci U S A 110: 8278‐8283, 2013.
 23.Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 28: 1654‐1659, 2008.
 24.Araneta MR, Barrett‐Connor E. Ethnic differences in visceral adipose tissue and type 2 diabetes: Filipino, African‐American, and white women. Obesity Res 13: 1458‐1465, 2005.
 25.Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose‐specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79‐83, 1999.
 26.Aron‐Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A, Aissat A, Guerre‐Millo M, Clement K. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous, omental depots and after weight loss. J Clin Endocrinol Metab 94: 4619‐4623, 2009.
 27.Auerbach P, Nordby P, Bendtsen LQ, Mehlsen JL, Basnet SK, Vestergaard H, Ploug T, Stallknecht B. Differential effects of endurance training and weight loss on plasma adiponectin multimers and adipose tissue macrophages in younger, moderately overweight men. Am J Physiol Regul Integr Comp Physiol 305: R490‐R498, 2013.
 28.Baena‐Fustegueras JA, Pardina E, Balada E, Ferrer R, Catalan R, Rivero J, Casals I, Lecube A, Fort JM, Vargas V, Peinado‐Onsurbe J. Soluble CD40 ligand in morbidly obese patients: Effect of body mass index on recovery to normal levels after gastric bypass surgery. JAMA Surg 148: 151‐156, 2013.
 29.Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation and insulin resistance. Eur Cytokine Netw 17: 4‐12, 2006.
 30.Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL‐6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87: 2084‐2089, 2002.
 31.Basu R, Breda E, Oberg AL, Powell CC, Dalla Man C, Basu A, Vittone JL, Klee GG, Arora P, Jensen MD, Toffolo G, Cobelli C, Rizza RA. Mechanisms of the age‐associated deterioration in glucose tolerance: Contribution of alterations in insulin secretion, action, and clearance. Diabetes 52: 1738‐1748, 2003.
 32.Bates SH, Kulkarni RN, Seifert M, Myers MG, Jr. Roles for leptin receptor/STAT3‐dependent and ‐independent signals in the regulation of glucose homeostasis. Cell Metab 1: 169‐178, 2005.
 33.Batt R, Mialhe P. Insulin resistance of the inherently obese mouse–obob. Nature 212: 289‐290, 1966.
 34.Becker L, Liu NC, Averill MM, Yuan W, Pamir N, Peng Y, Irwin AD, Fu X, Bornfeldt KE, Heinecke JW. Unique proteomic signatures distinguish macrophages and dendritic cells. PLoS One 7: e33297, 2012.
 35.Benoit B, Plaisancie P, Awada M, Geloen A, Estienne M, Capel F, Malpuech‐Brugere C, Debard C, Pesenti S, Morio B, Vidal H, Rieusset J, Michalski MC. High‐fat diet action on adiposity, inflammation, and insulin sensitivity depends on the control low‐fat diet. Nutr Res 33: 952‐960, 2013.
 36.Bergman RN, Stefanovski D, Buchanan TA, Sumner AE, Reynolds JC, Sebring NG, Xiang AH, Watanabe RM. A better index of body adiposity. Obesity (Silver Spring) 19: 1083‐1089, 2011.
 37.Bertola A, Ciucci T, Rousseau D, Bourlier V, Duffaut C, Bonnafous S, Blin‐Wakkach C, Anty R, Iannelli A, Gugenheim J, Tran A, Bouloumie A, Gual P, Wakkach A. Identification of adipose tissue dendritic cells correlated with obesity‐associated insulin‐resistance and inducing Th17 responses in mice and patients. Diabetes 61: 2238‐2247, 2012.
 38.Best JD, Kahn SE, Ader M, Watanabe RM, Ni TC, Bergman RN. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19: 1018‐1030, 1996.
 39.Bierman EL, Bagdade JD, Porte D, Jr. Obesity, diabetes: The odd couple. Am J Clin Nutr 21: 1434‐1437, 1968.
 40.Bigornia SJ, Farb MG, Mott MM, Hess DT, Carmine B, Fiscale A, Joseph L, Apovian CM, Gokce N. Relation of depot‐specific adipose inflammation to insulin resistance in human obesity. Nutr Diabetes 2: e30, 2012.
 41.Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand 185: 351‐356, 1969.
 42.Blachnio‐Zabielska AU, Baranowski M, Hirnle T, Zabielski P, Lewczuk A, Dmitruk I, Gorski J. Increased bioactive lipids content in human subcutaneous and epicardial fat tissue correlates with insulin resistance. Lipids 47: 1131‐1141, 2012.
 43.Blanco‐Colio LM, Tunon J, Martin‐Ventura JL, Egido J. Anti‐inflammatory and immunomodulatory effects of statins. Kidney Int 63: 12‐23, 2003.
 44.Bluher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol 21: 38‐43, 2010.
 45.Bluher M. Are metabolically healthy obese individuals really healthy? Eur J Endocrinol 171: R209‐R219, 2014.
 46.Bluher M, Kloting N, Wueest S, Schoenle EJ, Schon MR, Dietrich A, Fasshauer M, Stumvoll M, Konrad D. Fas and FasL expression in human adipose tissue is related to obesity, insulin resistance, and type 2 diabetes. J Clin Endocrinol Metab 99: E36‐E44, 2014.
 47.Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid‐induced inhibition of glucose uptake. J Clin Invest 93: 2438‐2446, 1994.
 48.Bogardus C, Lillioja S, Mott D, Reaven GR, Kashiwagi A, Foley JE. Relationship between obesity and maximal insulin‐stimulated glucose uptake in vivo and in vitro in man. Int J Obes 9 (Suppl 1): 149, 1985.
 49.Bonora E. Relationship between regional fat distribution and insulin resistance. Int J Obes Relat Metab Disord 24 (Suppl 2): S32‐S35, 2000.
 50.Bourlier V, Zakaroff‐Girard A, Miranville A, De Barros S, Maumus M, Sengenes C, Galitzky J, Lafontan M, Karpe F, Frayn KN, Bouloumie A. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 117: 806‐815, 2008.
 51.Breslin WL, Strohacker K, Carpenter KC, Esposito L, McFarlin BK. Weight gain in response to high‐fat feeding in CD‐1 male mice. Lab Anim 44: 231‐237, 2010.
 52.Brethauer SA, Heneghan HM, Eldar S, Gatmaitan P, Huang H, Kashyap S, Gornik HL, Kirwan JP, Schauer PR. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc 25: 2650‐2659, 2011.
 53.Browning LM, Krebs JD, Magee EC, Fruhbeck G, Jebb SA. Circulating markers of inflammation and their link to indices of adiposity. Obes Facts 1: 259‐265, 2008.
 54.Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz‐Schughart LA, Scholmerich J, Bollheimer LC. Defining high‐fat‐diet rat models: Metabolic and molecular effects of different fat types. J Mol Endocrinol 36: 485‐501, 2006.
 55.Bultman SJ, Michaud EJ, Woychik RP. Molecular characterization of the mouse agouti locus. Cell 71: 1195‐1204, 1992.
 56.Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery‐induced weight loss. Diabetes 54: 2277‐2286, 2005.
 57.Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, Basdevant A, Bar Hen A, Bedossa P, Guerre‐Millo M, Clement K. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55: 1554‐1561, 2006.
 58.Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia‐induced inflammation in high‐fat diet‐induced obesity and diabetes in mice. Diabetes 57: 1470‐1481, 2008.
 59.Capel F, Klimcakova E, Viguerie N, Roussel B, Vitkova M, Kovacikova M, Polak J, Kovacova Z, Galitzky J, Maoret JJ, Hanacek J, Pers TH, Bouloumie A, Stich V, Langin D. Macrophages and adipocytes in human obesity: Adipose tissue gene expression and insulin sensitivity during calorie restriction and weight stabilization. Diabetes 58: 1558‐1567, 2009.
 60.Carneiro IP, Elliott SA, Siervo M, Padwal R, Bertoli S, Battezzati A, Prado CM. Is obesity associated with altered energy expenditure? Adv Nutr 7: 476‐487, 2016.
 61.Castoldi A, Naffah de Souza C, Camara NO, Moraes‐Vieira PM. The macrophage switch in obesity development. Front Immunol 6: 637, 2015.
 62.Cavelti‐Weder C, Babians‐Brunner A, Keller C, Stahel MA, Kurz‐Levin M, Zayed H, Solinger AM, Mandrup‐Poulsen T, Dinarello CA, Donath MY. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35: 1654‐1662, 2012.
 63.Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6 year follow‐up study of the METSIM cohort. Diabetologia 58: 1109‐1117, 2015.
 64.Cefalu WT, Wang ZQ, Werbel S, Bell‐Farrow A, Crouse JR, 3rd, Hinson WH, Terry JG, Anderson R. Contribution of visceral fat mass to the insulin resistance of aging. Metabolism 44: 954‐959, 1995.
 65.Centers for Disease Control, Prevention. National Diabetes Statistics Report, 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national‐diabetes‐statistics‐report.pdf. Accessed on August 31, 2017.
 66.Ceriello A. Thiazolidinediones as anti‐inflammatory and anti‐atherogenic agents. Diabetes/Metab Res Rev 24: 14‐26, 2008.
 67.Chakaroun R, Raschpichler M, Kloting N, Oberbach A, Flehmig G, Kern M, Schon MR, Shang E, Lohmann T, Dressler M, Fasshauer M, Stumvoll M, Bluher M. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 61: 706‐714, 2012.
 68.Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA 301: 2129‐2140, 2009.
 69.Chandrasekharan JA, Sharma‐Walia N. Lipoxins: Nature's way to resolve inflammation. J Inflamm Res 8: 181‐192, 2015.
 70.Chang SK, Kohlgruber AC, Mizoguchi F, Michelet X, Wolf BJ, Wei K, Lee PY, Lynch L, Duquette D, Ceperuelo‐Mallafre V, Banks AS, Brenner MB. Stromal cell cadherin‐11 regulates adipose tissue inflammation and diabetes. J Clin Invest 127: 3300‐3312, 2017.
 71.Chaurasia B, Kaddai VA, Lancaster GI, Henstridge DC, Sriram S, Galam DL, Gopalan V, Prakash KN, Velan SS, Bulchand S, Tsong TJ, Wang M, Siddique MM, Yuguang G, Sigmundsson K, Mellet NA, Weir JM, Meikle PJ, Bin MYMS, Shabbir A, Shayman JA, Hirabayashi Y, Shiow ST, Sugii S, Summers SA. Adipocyte ceramides regulate subcutaneous adipose browning, inflammation, and metabolism. Cell Metab 24: 820‐834, 2016.
 72.Chavez JA, Summers SA. A ceramide‐centric view of insulin resistance. Cell Metab 15: 585‐594, 2012.
 73.Chawla A, Nguyen KD, Goh YP. Macrophage‐mediated inflammation in metabolic disease. Nat Rev Immunol 11: 738‐749, 2011.
 74.Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491‐495, 1996.
 75.Cho CH, Koh YJ, Han J, Sung HK, Jong Lee H, Morisada T, Schwendener RA, Brekken RA, Kang G, Oike Y, Choi TS, Suda T, Yoo OJ, Koh GY. Angiogenic role of LYVE‐1‐positive macrophages in adipose tissue. Circ Res 100: e47‐e57, 2007.
 76.Choe SS, Shin KC, Ka S, Lee YK, Chun JS, Kim JB. Macrophage HIF‐2alpha ameliorates adipose tissue inflammation and insulin resistance in obesity. Diabetes 63: 3359‐3371, 2014.
 77.Chun TH, Inoue M, Morisaki H, Yamanaka I, Miyamoto Y, Okamura T, Sato‐Kusubata K, Weiss SJ. Genetic link between obesity and MMP14‐dependent adipogenic collagen turnover. Diabetes 59: 2484‐2494, 2010.
 78.Cildir G, Akincilar SC, Tergaonkar V. Chronic adipose tissue inflammation: All immune cells on the stage. Trends Mol Med 19: 487‐500, 2013.
 79.Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46: 2347‐2355, 2005.
 80.Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 46: 459‐469, 2003.
 81.Coleman DL. Diabetes‐obesity syndromes in mice. Diabetes 31: 1‐6, 1982.
 82.Collaboration NCDRF. Trends in adult body‐mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population‐based measurement studies with 19.2 million participants. Lancet 387: 1377‐1396, 2016.
 83.Collaboration NCDRF. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population‐based studies with 4.4 million participants. Lancet 387: 1513‐1530, 2016.
 84.Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145: 367‐383, 2004.
 85.Conte C, Fabbrini E, Kars M, Mittendorfer B, Patterson BW, Klein S. Multiorgan insulin sensitivity in lean and obese subjects. Diabetes Care 35: 1316‐1321, 2012.
 86.Coon PJ, Rogus EM, Drinkwater D, Muller DC, Goldberg AP. Role of body fat distribution in the decline in insulin sensitivity and glucose tolerance with age. J Clin Endocrinol Metab 75: 1125‐1132, 1992.
 87.Cottam DR, Mattar SG, Barinas‐Mitchell E, Eid G, Kuller L, Kelley DE, Schauer PR. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: Implications and effects of weight loss. Obes Surg 14: 589‐600, 2004.
 88.Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF‐1alpha is essential for myeloid cell‐mediated inflammation. Cell 112: 645‐657, 2003.
 89.Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett‐Connor E, Temprosa M. Statin use and risk of developing diabetes: Results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care 5: e000438, 2017.
 90.Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: Inflammation, fibrosis, and impaired angiogenesis. J Clin Invest 127: 74‐82, 2017.
 91.Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski‐Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly‐Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 172: 144‐152, 2012.
 92.Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R, Bouloumie A. From blood monocytes to adipose tissue‐resident macrophages: Induction of diapedesis by human mature adipocytes. Diabetes 53: 1285‐1292, 2004.
 93.Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49: 744‐747, 2006.
 94.Davies LC, Rosas M, Jenkins SJ, Liao CT, Scurr MJ, Brombacher F, Fraser DJ, Allen JE, Jones SA, Taylor PR. Distinct bone marrow‐derived and tissue‐resident macrophage lineages proliferate at key stages during inflammation. Nat Commun 4: 1886, 2013.
 95.Davis JE, Gabler NK, Walker‐Daniels J, Spurlock ME. Tlr‐4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) 16: 1248‐1255, 2008.
 96.Deiuliis JA, Oghumu S, Duggineni D, Zhong J, Rutsky J, Banerjee A, Needleman B, Mikami D, Narula V, Hazey J, Satoskar AR, Rajagopalan S. CXCR3 modulates obesity‐induced visceral adipose inflammation and systemic insulin resistance. Obesity (Silver Spring) 22: 1264‐1274, 2014.
 97.Dietze‐Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance‐inducing factors. Diabetes 54: 2003‐2011, 2005.
 98.Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, Basdevant A, Guerre‐Millo M, Poitou C, Zucker JD, Bedossa P, Clement K. Fibrosis in human adipose tissue: Composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 59: 2817‐2825, 2010.
 99.Dominguez H, Storgaard H, Rask‐Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, Spohr C, Kober L, Vaag A, Torp‐Pedersen C. Metabolic and vascular effects of tumor necrosis factor‐alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42: 517‐525, 2005.
 100.Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343‐1351, 2005.
 101.Dube S, Errazuriz‐Cruzat I, Basu A, Basu R. The forgotten role of glucose effectiveness in the regulation of glucose tolerance. Curr Diab Rep 15: 605, 2015.
 102.Duffaut C, Zakaroff‐Girard A, Bourlier V, Decaunes P, Maumus M, Chiotasso P, Sengenes C, Lafontan M, Galitzky J, Bouloumie A. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arterioscler Thromb Vasc Biol 29: 1608‐1614, 2009.
 103.Eglit T, Ringmets I, Lember M. Obesity, high‐molecular‐weight (HMW) adiponectin, and metabolic risk factors: Prevalence and gender‐specific associations in Estonia. PLoS One 8: e73273, 2013.
 104.Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, Wielinga PY, Schraenen A, Lemaire K, Debray S, Van Lommel L, Pospisilik JA, Tschopp O, Schultze SM, Malipiero U, Esterbauer H, Ellingsgaard H, Rutti S, Schuit FC, Lutz TA, Boni‐Schnetzler M, Konrad D, Donath MY. Toll‐like receptor 2‐deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high‐fat diet. Diabetologia 53: 1795‐1806, 2010.
 105.Eissing L, Scherer T, Todter K, Knippschild U, Greve JW, Buurman WA, Pinnschmidt HO, Rensen SS, Wolf AM, Bartelt A, Heeren J, Buettner C, Scheja L. De novo lipogenesis in human fat and liver is linked to ChREBP‐beta and metabolic health. Nat Commun 4: 1528, 2013.
 106.Elgazar‐Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intra‐abdominal fat early in the course of high‐fat feeding. J Lipid Res 49: 1894‐1903, 2008.
 107.Elisha B, Karelis AD, Imbeault P, Rabasa‐Lhoret R. Effects of acute hyperinsulinaemia on total and high‐molecular‐weight adiponectin concentration in metabolically healthy but obese postmenopausal women: A Montreal‐Ottawa New Emerging Team (MONET) study. Diabetes Metab 36: 319‐321, 2010.
 108.Emery CF, Fondow MD, Schneider CM, Christofi FL, Hunt C, Busby AK, Needleman BJ, Melvin WS, Elsayed‐Awad HM. Gastric bypass surgery is associated with reduced inflammation and less depression: A preliminary investigation. Obes Surg 17: 759‐763, 2007.
 109.Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, Mohlig M, Pfeiffer AF, Luft FC, Sharma AM. Association between adiponectin and mediators of inflammation in obese women. Diabetes 52: 942‐947, 2003.
 110.Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll‐like receptor signaling. Arterioscler Thromb, Vasc Biol 29: 1944‐1949, 2009.
 111.Erusalimsky JD. Vascular endothelial senescence: From mechanisms to pathophysiology. J Appl Physiol (1985) 106: 326‐332, 2009.
 112.Esser N, L'Homme L, De Roover A, Kohnen L, Scheen AJ, Moutschen M, Piette J, Legrand‐Poels S, Paquot N. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 56: 2487‐2497, 2013.
 113.Esser N, Legrand‐Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105: 141‐150, 2014.
 114.Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 33: 68‐75, 1984.
 115.Fabbrini E, Cella M, McCartney SA, Fuchs A, Abumrad NA, Pietka TA, Chen Z, Finck BN, Han DH, Magkos F, Conte C, Bradley D, Fraterrigo G, Eagon JC, Patterson BW, Colonna M, Klein S. Association between specific adipose tissue CD4+ T‐cell populations and insulin resistance in obese individuals. Gastroenterology 145: 366‐374 e1‐3, 2013.
 116.Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106: 15430‐15435, 2009.
 117.Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail‐Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 50: 537‐543, 2013.
 118.Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. VitamHorm 74: 443‐477, 2006.
 119.Fantuzzi G. Adipose tissue, adipokines and inflammation. J Allergy Clin Immunol 115: 911‐919; quiz 920, 2005.
 120.Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin‐6 in 3T3‐L1 adipocytes. Biochem Biophys Res Commun 301: 1045‐1050, 2003.
 121.Ferrannini E, Camastra S, Coppack SW, Fliser D, Golay A, Mitrakou A. Insulin action and non‐esterified fatty acids. The European Group for the Study of Insulin Resistance (EGIR). Proc Nutr Soc 56: 753‐761, 1997.
 122.Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15: 930‐939, 2009.
 123.Filippin‐Monteiro FB, de Oliveira EM, Sandri S, Knebel FH, Albuquerque RC, Campa A. Serum amyloid A is a growth factor for 3T3‐L1 adipocytes, inhibits differentiation and promotes insulin resistance. Int J Obes (Lond) 36: 1032‐1039, 2012.
 124.Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest 71: 1523‐1535, 1983.
 125.Finkelstein EA, DiBonaventura M, Burgess SM, Hale BC. The costs of obesity in the workplace. J Occup Environ Med 52: 971‐976, 2010.
 126.Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: Payer‐ and service‐specific estimates. Health Aff (Millwood) 28: w822‐w831, 2009.
 127.Fisher FM, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, Kumar S. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo‐Asian males. Diabetologia 48: 1084‐1087, 2005.
 128.Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight, obesity in the United States: Prevalence and trends, 1960‐1994. Int J Obes Relat Metab Disord 22: 39‐47, 1998.
 129.Flegal KM, Kruszon‐Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315: 2284‐2291, 2016.
 130.Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31: 289‐294, 2008.
 131.Fontana L. Modulating human aging and age‐associated diseases. Biochim Biophys Acta 1790: 1133‐1138, 2009.
 132.Fraulob JC, Ogg‐Diamantino R, Fernandes‐Santos C, Aguila MB, Mandarim‐de‐Lacerda CA. A mouse model of metabolic syndrome: Insulin resistance, fatty liver and non‐alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr 46: 212‐223, 2010.
 133.Fresno M, Alvarez R, Cuesta N. Toll‐like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem 117: 151‐164, 2011.
 134.Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin‐6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847‐850, 1998.
 135.Fujisaka S, Usui I, Ikutani M, Aminuddin A, Takikawa A, Tsuneyama K, Mahmood A, Goda N, Nagai Y, Takatsu K, Tobe K. Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF‐1alpha‐dependent and HIF‐1alpha‐independent manner in obese mice. Diabetologia 56: 1403‐1412, 2013.
 136.Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid‐binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 118: 2640‐2650, 2008.
 137.Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752‐1761, 2004.
 138.Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: An adipokine‐mediated process? Diabetes 51: 2951‐2958, 2002.
 139.Garcia MC, Wernstedt I, Berndtsson A, Enge M, Bell M, Hultgren O, Horn M, Ahren B, Enerback S, Ohlsson C, Wallenius V, Jansson JO. Mature‐onset obesity in interleukin‐1 receptor I knockout mice. Diabetes 55: 1205‐1213, 2006.
 140.Garg A. Acquired and inherited lipodystrophies. New Engl J Med 350: 1220‐1234, 2004.
 141.Gavi S, Qurashi S, Melendez MM, Mynarcik DC, McNurlan MA, Gelato MC. Plasma retinol‐binding protein‐4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes: Response to Cho et al. Diabetes Care 30: e7; author reply e8, 2007.
 142.Giugliano D, Sacca L, Scognamiglio G, Ungaro B, Torella R. Influence of acetylsalicylic acid on glucose turnover in normal man. Diabete Metab 8: 279‐282, 1982.
 143.Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE, Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. Ann Intern Med 159: 1‐12, 2013.
 144.Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE, Team T‐TDS. The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial. Ann Intern Med 152: 346‐357, 2010.
 145.Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 1: 36‐43, 2008.
 146.Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46: 1579‐1585, 1997.
 147.Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Cajlakovic M, Ribitsch V, Clement K, Blaak EE. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization and inflammation. Circulation 124: 67‐76, 2011.
 148.Gordon RS, Jr., Cherkes A. Unesterified fatty acid in human blood plasma. J Clin Invest 35: 206‐212, 1956.
 149.Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3: 23‐35, 2003.
 150.Gosejacob D, Jager PS, Vom Dorp K, Frejno M, Carstensen AC, Kohnke M, Degen J, Dormann P, Hoch M. Ceramide synthase 5 is essential to maintain C16:0‐ceramide pools and contributes to the development of diet‐induced obesity. J Biol Chem 291: 6989‐7003, 2016.
 151.Goyal R, Faizy AF, Siddiqui SS, Singhai M. Evaluation of TNF‐alpha and IL‐6 levels in obese and non‐obese diabetics: Pre‐ and postinsulin effects. N Am J Med Sci 4: 180‐184, 2012.
 152.Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol‐binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New Engl J Med 354: 2552‐2563, 2006.
 153.Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 78: 783‐809, 1998.
 154.Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte biology. Adipocyte stress: The endoplasmic reticulum and metabolic disease. J Lipid Res 48: 1905‐1914, 2007.
 155.Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 29: 415‐445, 2011.
 156.Grigsby RJ, Dobrowsky RT. Inhibition of ceramide production reverses TNF‐induced insulin resistance. Biochem Biophys Res Commun 287: 1121‐1124, 2001.
 157.Gumbau V, Bruna M, Canelles E, Guaita M, Mulas C, Bases C, Celma I, Puche J, Marcaida G, Oviedo M, Vazquez A. A prospective study on inflammatory parameters in obese patients after sleeve gastrectomy. Obes Surg 24: 903‐908, 2014.
 158.Gupta D, Krueger CB, Lastra G. Over‐nutrition, obesity and insulin resistance in the development of beta‐cell dysfunction. Curr Diabetes Rev 8: 76‐83, 2012.
 159.Gutierrez DA, Kennedy A, Orr JS, Anderson EK, Webb CD, Gerrald WK, Hasty AH. Aberrant accumulation of undifferentiated myeloid cells in the adipose tissue of CCR2‐deficient mice delays improvements in insulin sensitivity. Diabetes 60: 2820‐2829, 2011.
 160.Haase J, Weyer U, Immig K, Kloting N, Bluher M, Eilers J, Bechmann I, Gericke M. Local proliferation of macrophages in adipose tissue during obesity‐induced inflammation. Diabetologia 57: 562‐571, 2014.
 161.Hadad N, Burgazliev O, Elgazar‐Carmon V, Solomonov Y, Wueest S, Item F, Konrad D, Rudich A, Levy R. Induction of cytosolic phospholipase a2alpha is required for adipose neutrophil infiltration and hepatic insulin resistance early in the course of high‐fat feeding. Diabetes 62: 3053‐3063, 2013.
 162.Hagman DK, Larson I, Kuzma JN, Cromer G, Makar K, Rubinow KB, Foster‐Schubert KE, van Yserloo B, Billing PS, Landerholm RW, Crouthamel M, Flum DR, Cummings DE, Kratz M. The short‐term and long‐term effects of bariatric/metabolic surgery on subcutaneous adipose tissue inflammation in humans. Metabolism 70: 12‐22, 2017.
 163.Halberg N, Khan T, Trujillo ME, Wernstedt‐Asterholm I, Attie AD, Sherwani S, Wang ZV, Landskroner‐Eiger S, Dineen S, Magalang UJ, Brekken RA, Scherer PE. Hypoxia‐inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 29: 4467‐4483, 2009.
 164.Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, Rydkina E, Vujcic S, Balan K, Gitlin I, Leonova K, Polinsky A, Chernova OB, Gudkov AV. Aging of mice is associated with p16(Ink4a)‐ and beta‐galactosidase‐positive macrophage accumulation that can be induced in young mice by senescent cells. Aging (Albany NY) 8: 1294‐1315, 2016.
 165.Han MS, Jung DY, Morel C, Lakhani SA, Kim JK, Flavell RA, Davis RJ. JNK expression by macrophages promotes obesity‐induced insulin resistance and inflammation. Science 339: 218‐222, 2013.
 166.Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87: 2395, 2002.
 167.Hardy OT, Perugini RA, Nicoloro SM, Gallagher‐Dorval K, Puri V, Straubhaar J, Czech MP. Body mass index‐independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surg Obes Relat Dis 7: 60‐67, 2011.
 168.Harlev A, Aricha‐Tamir B, Shaco‐Levy R, Tarnovscki T, Bashan N, Rudich A, Sheiner E, Press F, Wiznitzer A. Macrophage infiltration and stress‐signaling in omental and subcutaneous adipose tissue in diabetic pregnancies. J Matern Fetal Neonatal Med 27: 1189‐1194, 2014.
 169.Harman‐Boehm I, Bluher M, Redel H, Sion‐Vardy N, Ovadia S, Avinoach E, Shai I, Kloting N, Stumvoll M, Bashan N, Rudich A. Macrophage infiltration into omental versus subcutaneous fat across different populations: Effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 92: 2240‐2247, 2007.
 170.Harmon DB, Srikakulapu P, Kaplan JL, Oldham SN, McSkimming C, Garmey JC, Perry HM, Kirby JL, Prohaska TA, Gonen A, Hallowell P, Schirmer B, Tsimikas S, Taylor AM, Witztum JL, McNamara CA. Protective role for B‐1b B cells and IgM in obesity‐associated inflammation, glucose intolerance, and insulin resistance. Arterioscler Thromb Vasc Biol 36: 682‐691, 2016.
 171.Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58: 337‐343, 2009.
 172.Henegar C, Tordjman J, Achard V, Lacasa D, Cremer I, Guerre‐Millo M, Poitou C, Basdevant A, Stich V, Viguerie N, Langin D, Bedossa P, Zucker JD, Clement K. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol 9: R14, 2008.
 173.Heni M, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, Claussen CD, Stefan N, Haring HU, Fritsche A. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: A nuclear magnetic resonance study. Diabetes Metab Res Rev 26: 200‐205, 2010.
 174.Herman MA, Peroni OD, Villoria J, Schon MR, Abumrad NA, Bluher M, Klein S, Kahn BB. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 484: 333‐338, 2012.
 175.Hernandez‐Corbacho MJ, Canals D, Adada MM, Liu M, Senkal CE, Yi JK, Mao C, Luberto C, Hannun YA, Obeid LM. Tumor necrosis factor‐alpha (TNFalpha)‐induced ceramide generation via ceramide synthases regulates loss of focal adhesion kinase (FAK) and programmed cell death. J Biol Chem 290: 25356‐25373, 2015.
 176.Herrero L, Shapiro H, Nayer A, Lee J, Shoelson SE. Inflammation and adipose tissue macrophages in lipodystrophic mice. Proc Natl Acad Sci U S A 107: 240‐245, 2010.
 177.Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, Folian B, Subramaniam S, Gonzalez FJ, Glass CK, Ricote M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117: 1658‐1669, 2007.
 178.Hill AA, Reid Bolus W, Hasty AH. A decade of progress in adipose tissue macrophage biology. Immunol Rev 262: 134‐152, 2014.
 179.Hodson L, Humphreys SM, Karpe F, Frayn KN. Metabolic signatures of human adipose tissue hypoxia in obesity. Diabetes 62: 1417‐1425, 2013.
 180.Hoenicke L, Zender L. Immune surveillance of senescent cells–biological significance in cancer‐ and non‐cancer pathologies. Carcinogenesis 33: 1123‐1126, 2012.
 181.Holdstock C, Lind L, Engstrom BE, Ohrvall M, Sundbom M, Larsson A, Karlsson FA. CRP reduction following gastric bypass surgery is most pronounced in insulin‐sensitive subjects. Int J Obes (Lond) 29: 1275‐1280, 2005.
 182.Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA. Lipid‐induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid‐induced ceramide biosynthesis in mice. J Clin Invest 121: 1858‐1870, 2011.
 183.Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA. Inhibition of ceramide synthesis ameliorates glucocorticoid‐, saturated‐fat‐ and obesity‐induced insulin resistance. Cell Metab 5: 167‐179, 2007.
 184.Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE. Receptor‐mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55‐63, 2011.
 185.Holland WL, Xia JY, Johnson JA, Sun K, Pearson MJ, Sharma AX, Quittner‐Strom E, Tippetts TS, Gordillo R, Scherer PE. Inducible overexpression of adiponectin receptors highlight the roles of adiponectin‐induced ceramidase signaling in lipid and glucose homeostasis. Mol Metab 6: 267‐275, 2017.
 186.Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56: 901‐911, 2007.
 187.Hotamisligil GS. Inflammation and metabolic disorders. Nature 444: 860‐867, 2006.
 188.Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor‐alpha in human obesity and insulin resistance. J Clin Invest 95: 2409‐2415, 1995.
 189.Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor‐alpha: Direct role in obesity‐linked insulin resistance. Science 259: 87‐91, 1993.
 190.Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose‐specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595‐1599, 2000.
 191.Hsu WC, Araneta MR, Kanaya AM, Chiang JL, Fujimoto W. BMI cut points to identify at‐risk Asian Americans for type 2 diabetes screening. Diabetes Care 38: 150‐158, 2015.
 192.Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose‐specific gene dysregulated in obesity. J Biol Chem 271: 10697‐10703, 1996.
 193.Huang‐Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: Metabolic insights from a rare disorder. J Endocrinol 207: 245‐255, 2010.
 194.Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, Zlabinger GJ, Stulnig TM. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab 93: 3215‐3221, 2008.
 195.Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science 153: 1127‐1128, 1966.
 196.Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high‐dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109: 1321‐1326, 2002.
 197.Hunter GR, Gower BA, Kane BL. Age related shift in visceral fat. Int J Body Compos Res 8: 103‐108, 2010.
 198.Hyatt TC, Phadke RP, Hunter GR, Bush NC, Munoz AJ, Gower BA. Insulin sensitivity in African‐American and white women: Association with inflammation. Obesity (Silver Spring) 17: 276‐282, 2009.
 199.Iannelli A, Anty R, Piche T, Dahman M, Gual P, Tran A, Gugenheim J. Impact of laparoscopic Roux‐en‐Y gastric bypass on metabolic syndrome, inflammation and insulin resistance in super versus morbidly obese women. Obes Surg 19: 577‐582, 2009.
 200.Iannelli A, Anty R, Schneck AS, Tran A, Gugenheim J. Inflammation, insulin resistance, lipid disturbances, anthropometrics and metabolic syndrome in morbidly obese patients: A case control study comparing laparoscopic Roux‐en‐Y gastric bypass and laparoscopic sleeve gastrectomy. Surgery 149: 364‐370, 2011.
 201.Iannelli A, Martini F, Rodolphe A, Schneck AS, Gual P, Tran A, Hebuterne X, Gugenheim J. Body composition, anthropometrics, energy expenditure, systemic inflammation, in premenopausal women 1 year after laparoscopic Roux‐en‐Y gastric bypass. Surg Endosc 28: 500‐507, 2014.
 202.Illan‐Gomez F, Gonzalvez‐Ortega M, Orea‐Soler I, Alcaraz‐Tafalla MS, Aragon‐Alonso A, Pascual‐Diaz M, Perez‐Paredes M, Lozano‐Almela ML. Obesity and inflammation: Change in adiponectin, C‐reactive protein, tumour necrosis factor‐alpha and interleukin‐6 after bariatric surgery. Obes Surg 22: 950‐955, 2012.
 203.Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J Hered 41: 317‐318, 1950.
 204.Jaworski K, Sarkadi‐Nagy E, Duncan RE, Ahmadian M, Sul HS. Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. Am J Physiol Gastrointest Liver Physiol 293: G1‐G4, 2007.
 205.Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332: 1284‐1288, 2011.
 206.Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83: 1168‐1173, 1989.
 207.Ji Y, Sun S, Xia S, Yang L, Li X, Qi L. Short term high fat diet challenge promotes alternative macrophage polarization in adipose tissue via natural killer T cells and interleukin‐4. J Biol Chem 287: 24378‐24386, 2012.
 208.Jia L, Vianna CR, Fukuda M, Berglund ED, Liu C, Tao C, Sun K, Liu T, Harper MJ, Lee CE, Lee S, Scherer PE, Elmquist JK. Hepatocyte Toll‐like receptor 4 regulates obesity‐induced inflammation and insulin resistance. Nat Commun 5: 3878, 2014.
 209.Jiao P, Chen Q, Shah S, Du J, Tao B, Tzameli I, Yan W, Xu H. Obesity‐related upregulation of monocyte chemotactic factors in adipocytes: Involvement of nuclear factor‐kappaB and c‐Jun NH2‐terminal kinase pathways. Diabetes 58: 104‐115, 2009.
 210.Jin C, Flavell RA. Innate sensors of pathogen and stress: Linking inflammation to obesity. J Allergy Clin Immunol 132: 287‐294, 2013.
 211.Jo J, Guo J, Liu T, Mullen S, Hall KD, Cushman SW, Periwal V. Hypertrophy‐driven adipocyte death overwhelms recruitment under prolonged weight gain. Biophys J 99: 3535‐3544, 2010.
 212.Johannsen DL, Tchoukalova Y, Tam CS, Covington JD, Xie W, Schwarz JM, Bajpeyi S, Ravussin E. Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: Testing the “adipose tissue expandability” hypothesis. Diabetes Care 37: 2789‐2797, 2014.
 213.Jones PA, Scott‐Burden T. Activated macrophages digest the extracellular matrix proteins produced by cultured cells. Biochem Biophys Res Commun 86: 71‐77, 1979.
 214.Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26: 439‐451, 2005.
 215.Kahn SE, Cooper ME, Del Prato S. Pathophysiology, treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 383: 1068‐1083, 2014.
 216.Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840‐846, 2006.
 217.Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta‐cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663‐1672, 1993.
 218.Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka‐Kowatari N, Kumagai K, Sakamoto K, Kobayashi M, Yamauchi T, Ueki K, Oishi Y, Nishimura S, Manabe I, Hashimoto H, Ohnishi Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Nagai R, Kadowaki T. Overexpression of monocyte chemoattractant protein‐1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602‐26614, 2006.
 219.Kammoun HL, Kraakman MJ, Febbraio MA. Adipose tissue inflammation in glucose metabolism. Rev Endocr Metab Disord 15: 31‐44, 2014.
 220.Kanasaki K, Koya D. Biology of obesity: Lessons from animal models of obesity. J Biomed Biotechnol 2011: 197636, 2011.
 221.Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP‐1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494‐1505, 2006.
 222.Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L. Senescence surveillance of pre‐malignant hepatocytes limits liver cancer development. Nature 479: 547‐551, 2011.
 223.Kappes A, Loffler G. Influences of ionomycin, dibutyryl‐cycloAMP and tumour necrosis factor‐alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 32: 548‐554, 2000.
 224.Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: Time for a reevaluation. Diabetes 60: 2441‐2449, 2011.
 225.Katakura T, Miyazaki M, Kobayashi M, Herndon DN, Suzuki F. CCL17 and IL‐10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol 172: 1407‐1413, 2004.
 226.Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, Arnold SM. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 3: 411‐421, 2002.
 227.Kawasaki N, Asada R, Saito A, Kanemoto S, Imaizumi K. Obesity‐induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue. Sci Rep 2: 799, 2012.
 228.Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor‐alpha expression. Diabetes 52: 1779‐1785, 2003.
 229.Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin‐6 expression in human obesity and insulin resistance. Am J Physiol 280: E745‐E751, 2001.
 230.Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111‐2119, 1995.
 231.Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE. Metabolic dysregulation and adipose tissue fibrosis: Role of collagen VI. Mol Cell Biol 29: 1575‐1591, 2009.
 232.Khazen W, M'Bika JP, Tomkiewicz C, Benelli C, Chany C, Achour A, Forest C. Expression of macrophage‐selective markers in human and rodent adipocytes. FEBS Lett 579: 5631‐5634, 2005.
 233.Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R. Circulating levels of MCP‐1 and IL‐8 are elevated in human obese subjects and associated with obesity‐related parameters. Int J Obes (Lond) 30: 1347‐1355, 2006.
 234.Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: Systematic review, meta‐analysis, and empirical analysis. Value Health 19: 602‐613, 2016.
 235.Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE. Obesity‐associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117: 2621‐2637, 2007.
 236.Kintscher U, Hartge M, Hess K, Foryst‐Ludwig A, Clemenz M, Wabitsch M, Fischer‐Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Bluher M, Unger T, Wolf AM, Knippschild U, Hombach V, Marx N. T‐lymphocyte infiltration in visceral adipose tissue: A primary event in adipose tissue inflammation and the development of obesity‐mediated insulin resistance. Arterioscler Thromb Vasc Biol 28: 1304‐1310, 2008.
 237.Kishida K, Kim KK, Funahashi T, Matsuzawa Y, Kang HC, Shimomura I. Relationships between circulating adiponectin levels and fat distribution in obese subjects. J Atheroscler Thromb 18: 592‐595, 2011.
 238.Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, Stumvoll M, Bluher M. Insulin‐sensitive obesity. Am J Physiol 299: E506‐E515,
 239.Kodama S, Fujihara K, Ishiguro H, Horikawa C, Ohara N, Yachi Y, Tanaka S, Shimano H, Kato K, Hanyu O, Sone H. Quantitative relationship between cumulative risk alleles based on genome‐wide association studies and type 2 diabetes mellitus: A systematic review and meta‐analysis. J Epidemiol 28: 3‐18, 2018.
 240.Kodama S, Horikawa C, Fujihara K, Heianza Y, Hirasawa R, Yachi Y, Sugawara A, Tanaka S, Shimano H, Iida KT, Saito K, Sone H. Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist‐to‐height ratio: A meta‐analysis. Am J Epidemiol 176: 959‐969, 2012.
 241.Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13: 159‐175, 2013.
 242.Koliwad SK, Streeper RS, Monetti M, Cornelissen I, Chan L, Terayama K, Naylor S, Rao M, Hubbard B, Farese RV, Jr. DGAT1‐dependent triacylglycerol storage by macrophages protects mice from diet‐induced insulin resistance and inflammation. J Clin Invest 120: 756‐767, 2010.
 243.Konner AC, Bruning JC. Toll‐like receptors: Linking inflammation to metabolism. Trends Endocrinol Metab 22: 16‐23, 2011.
 244.Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134: 1369‐1375, 2008.
 245.Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 62: 726‐759, 2010.
 246.Korou LM, Doulamis IP, Tzanetakou IP, Mikhailidis DP, Perrea DN. The effect of biological age on the metabolic responsiveness of mice fed a high‐fat diet. Lab Anim 47: 241‐244, 2013.
 247.Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, Ferrante AW, Jr. Weight loss, lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 120: 3466‐3479, 2010.
 248.Koster A, Ding J, Stenholm S, Caserotti P, Houston DK, Nicklas BJ, You T, Lee JS, Visser M, Newman AB, Schwartz AV, Cauley JA, Tylavsky FA, Goodpaster BH, Kritchevsky SB, Harris TB, Health ABCs. Does the amount of fat mass predict age‐related loss of lean mass, muscle strength, and muscle quality in older adults? J Gerontol A Biol Sci Med Sci 66: 888‐895, 2011.
 249.Kotronen A, Yki‐Jarvinen H, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, Juurinen L, Lundbom N, Sorensen TI. Comparison of the relative contributions of intra‐abdominal and liver fat to components of the metabolic syndrome. Obesity (Silver Spring) 19: 23‐28, 2011.
 250.Kovacikova M, Sengenes C, Kovacova Z, Siklova‐Vitkova M, Klimcakova E, Polak J, Rossmeislova L, Bajzova M, Hejnova J, Hnevkovska Z, Bouloumie A, Langin D, Stich V. Dietary intervention‐induced weight loss decreases macrophage content in adipose tissue of obese women. Int J Obes (Lond) 35: 91‐98, 2011.
 251.Kowalski GM, Nicholls HT, Risis S, Watson NK, Kanellakis P, Bruce CR, Bobik A, Lancaster GI, Febbraio MA. Deficiency of haematopoietic‐cell‐derived IL‐10 does not exacerbate high‐fat‐diet‐induced inflammation or insulin resistance in mice. Diabetologia 54: 888‐899, 2011.
 252.Kraakman MJ, Murphy AJ, Jandeleit‐Dahm K, Kammoun HL. Macrophage polarization in obesity and type 2 diabetes: Weighing down our understanding of macrophage function? Front Immunol 5: 470, 2014.
 253.Kratz M, Coats BR, Hisert KB, Hagman D, Mutskov V, Peris E, Schoenfelt KQ, Kuzma JN, Larson I, Billing PS, Landerholm RW, Crouthamel M, Gozal D, Hwang S, Singh PK, Becker L. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab 20: 614‐625, 2014.
 254.Kratz M, Hagman DK, Kuzma JN, Foster‐Schubert KE, Chan CP, Stewart S, van Yserloo B, Westbrook EO, Arterburn DE, Flum DR, Cummings DE. Improvements in glycemic control after gastric bypass occur despite persistent adipose tissue inflammation. Obesity (Silver Spring) 24: 1438‐1445, 2016.
 255.Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: A 1H NMR spectroscopy study. Diabetologia 42: 113‐116, 1999.
 256.Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863‐25866, 2002.
 257.Lackey DE, Burk DH, Ali MR, Mostaedi R, Smith WH, Park J, Scherer PE, Seay SA, McCoin CS, Bonaldo P, Adams SH. Contributions of adipose tissue architectural and tensile properties toward defining healthy and unhealthy obesity. Am J Physiol 306: E233‐E246, 2014.
 258.Lancaster GI, Langley KG, Berglund NA, Kammoun HL, Reibe S, Estevez E, Weir J, Mellett NA, Pernes G, Conway JRW, Lee MKS, Timpson P, Murphy AJ, Masters SL, Gerondakis S, Bartonicek N, Kaczorowski DC, Dinger ME, Meikle PJ, Bond PJ, Febbraio MA. Evidence that TLR4 is not a receptor for saturated fatty acids but mediates lipid‐induced inflammation by reprogramming macrophage metabolism. Cell Metab 27: 1096‐1110 e5, 2018.
 259.Landgraf K, Rockstroh D, Wagner IV, Weise S, Tauscher R, Schwartze JT, Loffler D, Buhligen U, Wojan M, Till H, Kratzsch J, Kiess W, Bluher M, Korner A. Evidence of early alterations in adipose tissue biology and function and its association with obesity‐related inflammation and insulin resistance in children. Diabetes 64: 1249‐1261, 2015.
 260.Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup‐Poulsen T, Donath MY. Interleukin‐1‐receptor antagonist in type 2 diabetes mellitus. New Engl J Med 356: 1517‐1526, 2007.
 261.Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol 1: 335‐359, 1983.
 262.Lawler HM, Underkofler CM, Kern PA, Erickson C, Bredbeck B, Rasouli N. Adipose tissue hypoxia, inflammation, and fibrosis in obese insulin‐sensitive and obese insulin‐resistant subjects. J Clin Endocrinol Metab 101: 1422‐1428, 2016.
 263.Le KA, Ventura EE, Fisher JQ, Davis JN, Weigensberg MJ, Punyanitya M, Hu HH, Nayak KS, Goran MI. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care 34: 485‐490, 2011.
 264.Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity‐induced insulin resistance. Biochim Biophys Acta 1842: 446‐462, 2014.
 265.Lee JW, Im JA, Lee HR, Shim JY, Youn BS, Lee DC. Visceral adiposity is associated with serum retinol binding protein‐4 levels in healthy women. Obesity (Silver Spring) 15: 2225‐2232, 2007.
 266.Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med 34: 1‐11, 2013.
 267.Lee YS, Kim JW, Osborne O, Oh DY, Sasik R, Schenk S, Chen A, Chung H, Murphy A, Watkins SM, Quehenberger O, Johnson RS, Olefsky JM. Increased adipocyte O2 consumption triggers HIF‐1alpha, causing inflammation and insulin resistance in obesity. Cell 157: 1339‐1352, 2014.
 268.Lee YS, Li P, Huh JY, Hwang IJ, Lu M, Kim JI, Ham M, Talukdar S, Chen A, Lu WJ, Bandyopadhyay GK, Schwendener R, Olefsky J, Kim JB. Inflammation is necessary for long‐term but not short‐term high‐fat diet‐induced insulin resistance. Diabetes 60: 2474‐2483, 2011.
 269.Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. PPARgamma, the global map of adipogenesis and beyond. Trends Endocrinol Metab 25: 293‐302, 2014.
 270.Leibel RL, Edens NK, Fried SK. Physiologic basis for the control of body fat distribution in humans. Annu Rev Nutr 9: 417‐443, 1989.
 271.Lesniewski LA, Hosch SE, Neels JG, de Luca C, Pashmforoush M, Lumeng CN, Chiang SH, Scadeng M, Saltiel AR, Olefsky JM. Bone marrow‐specific Cap gene deletion protects against high‐fat diet‐induced insulin resistance. Nat Med 13: 455‐462, 2007.
 272.Lim YM, Lim H, Hur KY, Quan W, Lee HY, Cheon H, Ryu D, Koo SH, Kim HL, Kim J, Komatsu M, Lee MS. Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes. Nat Commun 5: 4934, 2014.
 273.Liska D, Dufour S, Zern TL, Taksali S, Cali AM, Dziura J, Shulman GI, Pierpont BM, Caprio S. Interethnic differences in muscle, liver and abdominal fat partitioning in obese adolescents. PLoS One 2: e569, 2007.
 274.Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN, Sukhova GK, Wolters PJ, Du J, Gorgun CZ, Doria A, Libby P, Blumberg RS, Kahn BB, Hotamisligil GS, Shi GP. Genetic deficiency and pharmacological stabilization of mast cells reduce diet‐induced obesity and diabetes in mice. Nat Med 15: 940‐945, 2009.
 275.Liu Q, Yuan B, Lo KA, Patterson HC, Sun Y, Lodish HF. Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc Natl Acad Sci U S A 109: 14568‐14573, 2012.
 276.Liu X, Miyazaki M, Flowers MT, Sampath H, Zhao M, Chu K, Paton CM, Joo DS, Ntambi JM. Loss of Stearoyl‐CoA desaturase‐1 attenuates adipocyte inflammation: Effects of adipocyte‐derived oleate. Arterioscler Thromb Vasc Biol 30: 31‐38, 2010.
 277.Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2: 637‐643, 1995.
 278.Lopez‐Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 153: 1194‐1217, 2013.
 279.Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, Gaulton KJ, Eicher JD, Sharp SJ, Luan J, De Lucia Rolfe E, Stewart ID, Wheeler E, Willems SM, Adams C, Yaghootkar H, Consortium EP‐I, Cambridge FC, Forouhi NG, Khaw KT, Johnson AD, Semple RK, Frayling T, Perry JR, Dermitzakis E, McCarthy MI, Barroso I, Wareham NJ, Savage DB, Langenberg C, O'Rahilly S, Scott RA. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 49: 17‐26, 2017.
 280.Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175‐184, 2007.
 281.Lutz TA, Woods SC. Overview of animal models of obesity. Curr Protoc Pharmacol Chapter 5: Unit5 61, 2012
 282.Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol 39: 1893‐1901, 2009.
 283.Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen‐like factor, apM1 (adiPose most abundant gene transcript 1). Biochem Biophys Res Commun 221: 286‐289, 1996.
 284.Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose‐derived protein. Diabetes 50: 2094‐2099, 2001.
 285.Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole‐body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 18: 1510‐1515, 2010.
 286.Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, de Las Fuentes L, He S, Okunade AL, Patterson BW, Klein S. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 23: 591‐601, 2016.
 287.Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty‐acid‐binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7: 699‐705, 2001.
 288.Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 34: 949‐959, 2010.
 289.Mantell BS, Stefanovic‐Racic M, Yang X, Dedousis N, Sipula IJ, O'Doherty RM. Mice lacking NKT cells but with a complete complement of CD8+T‐cells are not protected against the metabolic abnormalities of diet‐induced obesity. PLoS One 6: e19831, 2011.
 290.Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor‐associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549‐555, 2002.
 291.Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose, insulin resistance in development of type 2 diabetes mellitus: Results of a 25‐year follow‐up study. Lancet 340: 925‐929, 1992.
 292.Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000 Prime Rep 6: 13, 2014.
 293.Martinez JA, Milagro FI, Claycombe KJ, Schalinske KL. Epigenetics in adipose tissue, obesity, weight loss, and diabetes. Adv Nutr 5: 71‐81, 2014.
 294.Maskarinec G, Grandinetti A, Matsuura G, Sharma S, Mau M, Henderson BE, Kolonel LN. Diabetes prevalence and body mass index differ by ethnicity: The Multiethnic Cohort. Ethn Dis 19: 49‐55, 2009.
 295.Mathis D. Immunological goings‐on in visceral adipose tissue. Cell Metab 17: 851‐859, 2013.
 296.Matos LN, Giorelli Gde V, Dias CB. Correlation of anthropometric indicators for identifying insulin sensitivity and resistance. Sao Paulo Med J 129: 30‐35, 2011.
 297.Mauer J, Chaurasia B, Plum L, Quast T, Hampel B, Bluher M, Kolanus W, Kahn CR, Bruning JC. Myeloid cell‐restricted insulin receptor deficiency protects against obesity‐induced inflammation and systemic insulin resistance. PLoS Genet 6: e1000938, 2010.
 298.Mayer J, Bates MW, Dickie MM. Hereditary diabetes in genetically obese mice. Science 113: 746‐747, 1951.
 299.McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH, Roche HM. Lack of interleukin‐1 receptor I (IL‐1RI) protects mice from high‐fat diet‐induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 60: 1688‐1698, 2011.
 300.McLaughlin T, Deng A, Gonzales O, Aillaud M, Yee G, Lamendola C, Abbasi F, Connolly AJ, Sherman A, Cushman SW, Reaven G, Tsao PS. Insulin resistance is associated with a modest increase in inflammation in subcutaneous adipose tissue of moderately obese women. Diabetologia 51: 2303‐2308, 2008.
 301.McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab 96: E1756‐E1760, 2011.
 302.McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity 41: 36‐48, 2014.
 303.Meakin PJ, Morrison VL, Sneddon CC, Savinko T, Uotila L, Jalicy SM, Gabriel JL, Kang L, Ashford ML, Fagerholm SC. Mice lacking beta2‐integrin function remain glucose tolerant in spite of insulin resistance, neutrophil infiltration and inflammation. PLoS One 10: e0138872, 2015.
 304.Medzhitov R. Origin and physiological roles of inflammation. Nature 454: 428‐435, 2008.
 305.Meikle PJ, Summers SA. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol 13: 79‐91, 2017.
 306.Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988‐2012. JAMA 314: 1021‐1029, 2015.
 307.Menke A, Orchard TJ, Imperatore G, Bullard KM, Mayer‐Davis E, Cowie CC. The prevalence of type 1 diabetes in the United States. Epidemiology 24: 773‐774, 2013.
 308.Metter EJ, Conwit R, Tobin J, Fozard JL. Age‐associated loss of power and strength in the upper extremities in women and men. J Gerontol A Biol Sci Med Sci 52: B267‐B276, 1997.
 309.Meza‐Perez S, Randall TD. Immunological functions of the omentum. Trends Immunol 38: 526‐536, 2017.
 310.Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux‐en‐Y gastric bypass surgery. Surg Obes Relat Dis 7: 618‐624, 2011.
 311.Miller KN, Burhans MS, Clark JP, Howell PR, Polewski MA, DeMuth TM, Eliceiri KW, Lindstrom MJ, Ntambi JM, Anderson RM. Aging and caloric restriction impact adipose tissue, adiponectin, and circulating lipids. Aging Cell 16: 497‐507, 2017.
 312.Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: Role of telomere in endothelial dysfunction. Circulation 105: 1541‐1544, 2002.
 313.Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T, Nojima A, Nabetani A, Oike Y, Matsubara H, Ishikawa F, Komuro I. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 15: 1082‐1087, 2009.
 314.Minster RL, Hawley NL, Su CT, Sun G, Kershaw EE, Cheng H, Buhule OD, Lin J, Reupena MS, Viali S, Tuitele J, Naseri T, Urban Z, Deka R, Weeks DE, McGarvey ST. A thrifty variant in CREBRF strongly influences body mass index in Samoans. Nat Genet 48: 1049‐1054, 2016.
 315.Mittendorfer B, Magkos F, Fabbrini E, Mohammed BS, Klein S. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring) 17: 1872‐1877, 2009.
 316.Mitterberger MC, Lechner S, Mattesich M, Zwerschke W. Adipogenic differentiation is impaired in replicative senescent human subcutaneous adipose‐derived stromal/progenitor cells. J Gerontol A Biol Sci Med Sci 69: 13‐24, 2014.
 317.Miyazaki M, Bruggink SM, Ntambi JM. Identification of mouse palmitoyl‐coenzyme A Delta9‐desaturase. J Lipid Res 47: 700‐704, 2006.
 318.Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, Liu X, Ntambi JM. Hepatic stearoyl‐CoA desaturase‐1 deficiency protects mice from carbohydrate‐induced adiposity and hepatic steatosis. Cell Metab 6: 484‐496, 2007.
 319.Miyazaki M, Man WC, Ntambi JM. Targeted disruption of stearoyl‐CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J Nutr 131: 2260‐2268, 2001.
 320.Miyazaki M, Sampath H, Liu X, Flowers MT, Chu K, Dobrzyn A, Ntambi JM. Stearoyl‐CoA desaturase‐1 deficiency attenuates obesity and insulin resistance in leptin‐resistant obese mice. Biochem Biophys Res Commun 380: 818‐822, 2009.
 321.Mohamed‐Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin‐6, but not tumor necrosis factor‐alpha, in vivo. J Clin Endocrinol Metab 82: 4196‐4200, 1997.
 322.Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus‐Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: A transgenic mouse. Genes Dev 12: 3168‐3181, 1998.
 323.Monte SV, Caruana JA, Ghanim H, Sia CL, Korzeniewski K, Schentag JJ, Dandona P. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux‐en‐Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery 151: 587‐593, 2012.
 324.Monteiro R, de Castro PM, Calhau C, Azevedo I. Adipocyte size and liability to cell death. Obes Surg 16: 804‐806, 2006.
 325.Morinigo R, Casamitjana R, Delgado S, Lacy A, Deulofeu R, Conget I, Barcelo‐Batllori S, Gomis R, Vidal J. Insulin resistance, inflammation, and the metabolic syndrome following Roux‐en‐Y gastric bypass surgery in severely obese subjects. Diabetes Care 30: 1906‐1908, 2007.
 326.Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 443: 289‐295, 2006.
 327.Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, Kaser S, Kaser A, Tilg H. Anti‐inflammatory effects of excessive weight loss: Potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59: 1259‐1264, 2010.
 328.Moussa NM, Claycombe KJ. The yellow mouse obesity syndrome and mechanisms of agouti‐induced obesity. Obesity Res 7: 506‐514, 1999.
 329.Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low‐grade inflammation. J Endocrinol 222: R113‐R127, 2014.
 330.Mraz M, Lacinova Z, Drapalova J, Haluzikova D, Horinek A, Matoulek M, Trachta P, Kavalkova P, Svacina S, Haluzik M. The effect of very‐low‐calorie diet on mRNA expression of inflammation‐related genes in subcutaneous adipose tissue and peripheral monocytes of obese patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 96: E606‐E613, 2011.
 331.Muir LA, Neeley CK, Meyer KA, Baker NA, Brosius AM, Washabaugh AR, Varban OA, Finks JF, Zamarron BF, Flesher CG, Chang JS, DelProposto JB, Geletka L, Martinez‐Santibanez G, Kaciroti N, Lumeng CN, O'Rourke RW. Adipose tissue fibrosis, hypertrophy, and hyperplasia: Correlations with diabetes in human obesity. Obesity (Silver Spring) 24: 597‐605, 2016.
 332.Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, Cinti S. Dead adipocytes, detected as crown‐like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49: 1562‐1568, 2008.
 333.Murphy K, Travers P, Walport M. Janeway's Immunobiology. New York: Garland Science, Taylor & Francis Group, LLC, 2008.
 334.Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97: 11371‐11376, 2000.
 335.Nakano Y, Tobe T, Choi‐Miura NH, Mazda T, Tomita M. Isolation, characterization of GBP28, a novel gelatin‐binding protein purified from human plasma. J Biochem 120: 803‐812, 1996.
 336.Nathan C. Neutrophils, immunity: Challenges and opportunities. Nat Rev Immunol 6: 173‐182, 2006.
 337.Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab 57: 1102‐1106, 1983.
 338.Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, Mukundan L, Brombacher F, Locksley RM, Chawla A. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480: 104‐108, 2011.
 339.Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu‐Bryan R, Glass CK, Neels JG, Olefsky JM. A subpopulation of macrophages infiltrates hypertrophic adipose tissue, and is activated by free fatty acids via Toll‐like receptors 2 and 4 and JNK‐dependent pathways. J Biol Chem 282: 35279‐35292, 2007.
 340.Ni Y, Zhao L, Yu H, Ma X, Bao Y, Rajani C, Loo LW, Shvetsov YB, Yu H, Chen T, Zhang Y, Wang C, Hu C, Su M, Xie G, Zhao A, Jia W, Jia W. Circulating unsaturated fatty acids delineate the metabolic status of obese individuals. EBioMedicine 2: 1513‐1522, 2015.
 341.Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol 22: R741‐R752, 2012.
 342.Nicholls HT, Kowalski G, Kennedy DJ, Risis S, Zaffino LA, Watson N, Kanellakis P, Watt MJ, Bobik A, Bonen A, Febbraio M, Lancaster GI, Febbraio MA. Hematopoietic cell‐restricted deletion of CD36 reduces high‐fat diet‐induced macrophage infiltration and improves insulin signaling in adipose tissue. Diabetes 60: 1100‐1110, 2011.
 343.Nijhuis J, Rensen SS, Slaats Y, van Dielen FM, Buurman WA, Greve JW. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring) 17: 2014‐2018, 2009.
 344.Nishimoto S, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Murata C, Kim‐Kaneyama JR, Sato F, Bando M, Yagi S, Soeki T, Hayashi T, Imoto I, Sakaue H, Shimabukuro M, Sata M. Obesity‐induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv 2: e1501332, 2016.
 345.Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15: 914‐920, 2009.
 346.Nomiyama T, Perez‐Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschop MH, Bruemmer D. Osteopontin mediates obesity‐induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117: 2877‐2888, 2007.
 347.Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD. Loss of stearoyl‐CoA desaturase‐1 function protects mice against adiposity. Proc Natl Acad Sci U S A 99: 11482‐11486, 2002.
 348.O'Connell J, Lynch L, Cawood TJ, Kwasnik A, Nolan N, Geoghegan J, McCormick A, O'Farrelly C, O'Shea D. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 5: e9997, 2010.
 349.O'Rourke RW, White AE, Metcalf MD, Olivas AS, Mitra P, Larison WG, Cheang EC, Varlamov O, Corless CL, Roberts CT, Jr., Marks DL. Hypoxia‐induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. Diabetologia 54: 1480‐1490, 2011.
 350.O'Rourke RW, White AE, Metcalf MD, Winters BR, Diggs BS, Zhu X, Marks DL. Systemic inflammation and insulin sensitivity in obese IFN‐gamma knockout mice. Metabolism 61: 1152‐1161, 2012.
 351.Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti‐TNF‐alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881‐885, 1996.
 352.Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011‐2012. JAMA 311: 806‐814, 2014.
 353.Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. Acta Clin Belg 62: 218‐222, 2007.
 354.Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega‐3 fatty acid receptor mediating potent anti‐inflammatory and insulin‐sensitizing effects. Cell 142: 687‐698, 2010.
 355.Okamoto Y, Higashiyama H, Rong JX, McVey MJ, Kinoshita M, Asano S, Hansen MK. Comparison of mitochondrial and macrophage content between subcutaneous and visceral fat in db/db mice. Exp Mol Pathol 83: 73‐83, 2007.
 356.Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Ann Rev Physiol 72: 219‐246, 2010.
 357.Ortega Martinez de Victoria E, Xu X, Koska J, Francisco AM, Scalise M, Ferrante AW, Jr., Krakoff J. Macrophage content in subcutaneous adipose tissue: associations with adiposity, age, inflammatory markers, and whole‐body insulin action in healthy Pima Indians. Diabetes 58: 385‐393, 2009.
 358.Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306: 457‐461, 2004.
 359.Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure‐function studies of the adipocyte‐secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278: 9073‐9085, 2003.
 360.Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione‐mediated improvement in insulin sensitivity. J Biol Chem 279: 12152‐12162, 2004.
 361.Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S. Fetuin‐A acts as an endogenous ligand of TLR4 to promote lipid‐induced insulin resistance. Nat Med 18: 1279‐1285, 2012.
 362.Palmer AK, Kirkland JL. Aging and adipose tissue: Potential interventions for diabetes and regenerative medicine. Exp Gerontol 86: 97‐105, 2016.
 363.Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46: 983‐988, 1997.
 364.Pandolfi JB, Ferraro AA, Sananez I, Gancedo MC, Baz P, Billordo LA, Fainboim L, Arruvito L. ATP‐induced inflammation drives tissue‐resident Th17 cells in metabolically unhealthy obesity. J Immunol 196: 3287‐3296, 2016.
 365.Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non‐esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38: 1213‐1217, 1995.
 366.Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin‐resistant patients. J Clin Endocrinol Metab 85: 1316‐1319, 2000.
 367.Paradisi G, Smith L, Burtner C, Leaming R, Garvey WT, Hook G, Johnson A, Cronin J, Steinberg HO, Baron AD. Dual energy X‐ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 22: 1310‐1317, 1999.
 368.Pardina E, Ferrer R, Baena‐Fustegueras JA, Rivero J, Lecube A, Fort JM, Vargas V, Catalan R, Peinado‐Onsurbe J. Only C‐reactive protein, but not TNF‐alpha or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg 22: 131‐139, 2012.
 369.Park YS, Uddin MJ, Piao L, Hwang I, Lee JH, Ha H. Novel role of endogenous catalase in macrophage polarization in adipose tissue. Mediators Inflamm 2016: 8675905, 2016.
 370.Parks BW, Nam E, Org E, Kostem E, Norheim F, Hui ST, Pan C, Civelek M, Rau CD, Bennett BJ, Mehrabian M, Ursell LK, He A, Castellani LW, Zinker B, Kirby M, Drake TA, Drevon CA, Knight R, Gargalovic P, Kirchgessner T, Eskin E, Lusis AJ. Genetic control of obesity and gut microbiota composition in response to high‐fat, high‐sucrose diet in mice. Cell Metab 17: 141‐152, 2013.
 371.Parks BW, Sallam T, Mehrabian M, Psychogios N, Hui ST, Norheim F, Castellani LW, Rau CD, Pan C, Phun J, Zhou Z, Yang WP, Neuhaus I, Gargalovic PS, Kirchgessner TG, Graham M, Lee R, Tontonoz P, Gerszten RE, Hevener AL, Lusis AJ. Genetic architecture of insulin resistance in the mouse. Cell Metab 21: 334‐346, 2015.
 372.Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR. Reduced adipose tissue oxygenation in human obesity: Evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 58: 718‐725, 2009.
 373.Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes 2013: 489187, 2013.
 374.Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c‐positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8: 301‐309, 2008.
 375.Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109: 1345‐1350, 2002.
 376.Petersen PS, Lei X, Wolf RM, Rodriguez S, Tan SY, Little HC, Schweitzer MA, Magnuson TH, Steele KE, Wong GW. CTRP7 deletion attenuates obesity‐linked glucose intolerance, adipose tissue inflammation, and hepatic stress. Am J Physiol 312: E309‐E325, 2017.
 377.Pham CT. Neutrophil serine proteases: Specific regulators of inflammation. Nat Rev Immunol 6: 541‐550, 2006.
 378.Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche‐von Ameln A, Garcia‐Martin R, Sprott D, Moisidou M, Tzanavari T, Ludwig B, Baraban E, Ehrhart‐Bornstein M, Bornstein SR, Mziaut H, Solimena M, Karalis KP, Economopoulou M, Lambris JD, Chavakis T. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol 191: 4367‐4374, 2013.
 379.Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: The role of glucose, lipids and endotoxin. J Endocrinol 216: T1‐T15, 2013.
 380.Poggi M, Bastelica D, Gual P, Iglesias MA, Gremeaux T, Knauf C, Peiretti F, Verdier M, Juhan‐Vague I, Tanti JF, Burcelin R, Alessi MC. C3H/HeJ mice carrying a toll‐like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high‐fat diet. Diabetologia 50: 1267‐1276, 2007.
 381.Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive‐dose compared with moderate‐dose statin therapy: A meta‐analysis. JAMA 305: 2556‐2564, 2011.
 382.Prieur X, Mok CY, Velagapudi VR, Nunez V, Fuentes L, Montaner D, Ishikawa K, Camacho A, Barbarroja N, O'Rahilly S, Sethi JK, Dopazo J, Oresic M, Ricote M, Vidal‐Puig A. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 60: 797‐809, 2011.
 383.Qatanani M, Lazar MA. Mechanisms of obesity‐associated insulin resistance: Many choices on the menu. Genes Dev 21: 1443‐1455, 2007.
 384.Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, Dogra S, Ohman MK, Takeda K, Sugii S, Pewzner‐Jung Y, Futerman AH, Summers SA. CerS2 haploinsufficiency inhibits beta‐oxidation and confers susceptibility to diet‐induced steatohepatitis and insulin resistance. Cell Metab 20: 687‐695, 2014.
 385.Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 86: 5366‐5371, 2001.
 386.Randle PJ. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14: 263‐283, 1998.
 387.Randle PJ, Garland PB, Newsholme EA, Hales CN. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 131: 324‐333, 1965.
 388.Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Perusse L, Bouchard C. The human obesity gene map: The 2005 update. Obesity (Silver Spring) 14: 529‐644, 2006.
 389.Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37: 1020‐1024, 1988.
 390.Reid J, Macdougall AI, Andrews MM. Aspirin and diabetes mellitus. Br Med J 2: 1071‐1074, 1957.
 391.Rheinheimer J, de Souza BM, Cardoso NS, Bauer AC, Crispim D. Current role of the NLRP3 inflammasome on obesity and insulin resistance: A systematic review. Metabolism 74: 1‐9, 2017.
 392.Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T, Group CPI. Effects of interleukin‐1beta inhibition with canakinumab on hemoglobin A1c, lipids, C‐reactive protein, interleukin‐6, and fibrinogen: A phase IIb randomized, placebo‐controlled trial. Circulation 126: 2739‐2748, 2012.
 393.Robbins AL, Savage DB. The genetics of lipid storage and human lipodystrophies. Trends Mol Med 21: 433‐438, 2015.
 394.Robblee MM, Kim CC, Porter Abate J, Valdearcos M, Sandlund KL, Shenoy MK, Volmer R, Iwawaki T, Koliwad SK. Saturated fatty acids engage an IRE1alpha‐dependent pathway to activate the NLRP3 Inflammasome in myeloid cells. Cell Rep 14: 2611‐2623, 2016.
 395.Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid‐induced insulin resistance in humans. J Clin Invest 97: 2859‐2865, 1996.
 396.Rong JX, Qiu Y, Hansen MK, Zhu L, Zhang V, Xie M, Okamoto Y, Mattie MD, Higashiyama H, Asano S, Strum JC, Ryan TE. Adipose mitochondrial biogenesis is suppressed in db/db and high‐fat diet‐fed mice and improved by rosiglitazone. Diabetes 56: 1751‐1760, 2007.
 397.Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 156: 20‐44, 2014.
 398.Rowe JW, Minaker KL, Pallotta JA, Flier JS. Characterization of the insulin resistance of aging. J Clin Invest 71: 1581‐1587, 1983.
 399.Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 8: 101‐109, 2016.
 400.Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. J Cell Biol 208: 501‐512, 2015.
 401.Rytka JM, Wueest S, Schoenle EJ, Konrad D. The portal theory supported by venous drainage‐selective fat transplantation. Diabetes 60: 56‐63, 2011.
 402.Saberi M, Woods NB, de Luca C, Schenk S, Lu JC, Bandyopadhyay G, Verma IM, Olefsky JM. Hematopoietic cell‐specific deletion of toll‐like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high‐fat‐fed mice. Cell Metab 10: 419‐429, 2009.
 403.Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, Barrett T, Kim JK, Davis RJ. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322: 1539‐1543, 2008.
 404.Sabio G, Kennedy NJ, Cavanagh‐Kyros J, Jung DY, Ko HJ, Ong H, Barrett T, Kim JK, Davis RJ. Role of muscle c‐Jun NH2‐terminal kinase 1 in obesity‐induced insulin resistance. Mol Cell Biol 30: 106‐115, 2010.
 405.Sachithanandan N, Graham KL, Galic S, Honeyman JE, Fynch SL, Hewitt KA, Steinberg GR, Kay TW. Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance. Diabetes 60: 2023‐2031, 2011.
 406.Sahai A, Malladi P, Pan X, Paul R, Melin‐Aldana H, Green RM, Whitington PF. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: Role of short‐form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287: G1035‐G1043, 2004.
 407.Sams VG, Blackledge C, Wijayatunga N, Barlow P, Mancini M, Mancini G, Moustaid‐Moussa N. Effect of bariatric surgery on systemic and adipose tissue inflammation. Surg Endosc 30: 3499‐3504, 2015.
 408.Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL. Overnight lowering of free fatty acids with Acipimox improves insulin resistance, glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48: 1836‐1841, 1999.
 409.Satoh M, Andoh Y, Clingan CS, Ogura H, Fujii S, Eshima K, Nakayama T, Taniguchi M, Hirata N, Ishimori N, Tsutsui H, Onoe K, Iwabuchi K. Type II NKT cells stimulate diet‐induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance. PLoS One 7: e30568, 2012.
 410.Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: A collaborative meta‐analysis of randomised statin trials. Lancet 375: 735‐742, 2010.
 411.Sawada M, Kiyono T, Nakashima S, Shinoda J, Naganawa T, Hara S, Iwama T, Sakai N. Molecular mechanisms of TNF‐alpha‐induced ceramide formation in human glioma cells: P53‐mediated oxidant stress‐dependent and ‐independent pathways. Cell Death Differ 11: 997‐1008, 2004.
 412.Schafer MJ, White TA, Evans G, Tonne JM, Verzosa GC, Stout MB, Mazula DL, Palmer AK, Baker DJ, Jensen MD, Torbenson MS, Miller JD, Ikeda Y, Tchkonia T, van Deursen JM, Kirkland JL, LeBrasseur NK. Exercise prevents diet‐induced cellular senescence in adipose tissue. Diabetes 65: 1606‐1615, 2016.
 413.Scheja L, Heese B, Zitzer H, Michael MD, Siesky AM, Pospisil H, Beisiegel U, Seedorf K. Acute‐phase serum amyloid A as a marker of insulin resistance in mice. Exp Diabetes Res 2008: 230837, 2008.
 414.Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746‐26749, 1995.
 415.Schipper HS, Rakhshandehroo M, van de Graaf SF, Venken K, Koppen A, Stienstra R, Prop S, Meerding J, Hamers N, Besra G, Boon L, Nieuwenhuis EE, Elewaut D, Prakken B, Kersten S, Boes M, Kalkhoven E. Natural killer T cells in adipose tissue prevent insulin resistance. J Clin Invest 122: 3343‐3354, 2012.
 416.Schmidt‐Arras D, Rose‐John S. IL‐6 pathway in the liver: From physiopathology to therapy. J Hepatol 64: 1403‐1415, 2016.
 417.Schmitz J, Evers N, Awazawa M, Nicholls HT, Bronneke HS, Dietrich A, Mauer J, Bluher M, Bruning JC. Obesogenic memory can confer long‐term increases in adipose tissue but not liver inflammation and insulin resistance after weight loss. Mol Metab 5: 328‐339, 2016.
 418.Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, Rauterberg J, Lorkowski S. Production of type VI collagen by human macrophages: A new dimension in macrophage functional heterogeneity. J Immunol 180: 5707‐5719, 2008.
 419.Schulz C, Gomez Perdiguero E, Chorro L, Szabo‐Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SE, Pollard JW, Frampton J, Liu KJ, Geissmann F. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336: 86‐90, 2012.
 420.Schwartz MW, Seeley RJ, Tschop MH, Woods SC, Morton GJ, Myers MG, D'Alessio D. Cooperation between brain and islet in glucose homeostasis, diabetes. Nature 503: 59‐66, 2013.
 421.Shan B, Wang X, Wu Y, Xu C, Xia Z, Dai J, Shao M, Zhao F, He S, Yang L, Zhang M, Nan F, Li J, Liu J, Liu J, Jia W, Qiu Y, Song B, Han JJ, Rui L, Duan SZ, Liu Y. The metabolic ER stress sensor IRE1alpha suppresses alternative activation of macrophages and impairs energy expenditure in obesity. Nat Immunol 18: 519‐529, 2017.
 422.Sharma NK, Das SK, Mondal AK, Hackney OG, Chu WS, Kern PA, Rasouli N, Spencer HJ, Yao‐Borengasser A, Elbein SC. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J Clin Endocrinol Metab 93: 4532‐4541, 2008.
 423.Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid‐induced insulin resistance. J Clin Invest 116: 3015‐3025, 2006.
 424.Shi Y, Cheng D. Beyond triglyceride synthesis: The dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol 297: E10‐E18, 2009.
 425.Shimizu I, Yoshida Y, Moriya J, Nojima A, Uemura A, Kobayashi Y, Minamino T. Semaphorin3E‐induced inflammation contributes to insulin resistance in dietary obesity. Cell Metab 18: 491‐504, 2013.
 426.Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, Brown MS. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP‐1c in adipose tissue: Model for congenital generalized lipodystrophy. Genes Dev 12: 3182‐3194, 1998.
 427.Shirakawa K, Yan X, Shinmura K, Endo J, Kataoka M, Katsumata Y, Yamamoto T, Anzai A, Isobe S, Yoshida N, Itoh H, Manabe I, Sekai M, Hamazaki Y, Fukuda K, Minato N, Sano M. Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest 126: 4626‐4639, 2016.
 428.Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 116: 1793‐1801, 2006.
 429.Snodgrass RG, Boss M, Zezina E, Weigert A, Dehne N, Fleming I, Brune B, Namgaladze D. Hypoxia potentiates palmitate‐induced pro‐inflammatory activation of primary human macrophages. J Biol Chem 291: 413‐424, 2016.
 430.Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, Grivennikov S, Wynshaw‐Boris A, Scadeng M, Olefsky JM, Karin M. JNK1 in hematopoietically derived cells contributes to diet‐induced inflammation and insulin resistance without affecting obesity. Cell Metab 6: 386‐397, 2007.
 431.Soukas A, Cohen P, Socci ND, Friedman JM. Leptin‐specific patterns of gene expression in white adipose tissue. Genes Dev 14: 963‐980, 2000.
 432.Speakman J, Hambly C, Mitchell S, Krol E. Animal models of obesity. Obesity Rev 8(Suppl 1): 55‐61, 2007.
 433.Spencer M, Unal R, Zhu B, Rasouli N, McGehee RE, Jr., Peterson CA, Kern PA. Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance. J Clin Endocrinol Metab 96: E1990‐E1998, 2011.
 434.Spieker EA, Pyzocha N. Economic impact of obesity. Prim Care 43: 83‐95, viii‐ix, 2016.
 435.Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, Jala VR, Haribabu B. Deficiency of the leukotriene B4 receptor, BLT‐1, protects against systemic insulin resistance in diet‐induced obesity. J Immunol 187: 1942‐1949, 2011.
 436.Sramkova V, Rossmeislova L, Krauzova E, Kracmerova J, Koc M, Langin D, Stich V, Siklova M. Comparison of early (2 days) and later (28 days) response of adipose tissue to very low‐calorie diet in obese women. J Clin Endocrinol Metab 101: 5021‐5029, 2016.
 437.Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, Khor VK, Ahima RS, Grinspoon SK. TNF‐alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96: E146‐E150, 2011.
 438.Stefan N, Haring HU, Hu FB, Schulze MB. Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 1: 152‐162, 2013.
 439.Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring HU. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168: 1609‐1616, 2008.
 440.Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab 23: 770‐784, 2016.
 441.Steven S, Hollingsworth KG, Al‐Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very low‐calorie diet and 6 months of weight stability in type 2 diabetes: Pathophysiological changes in responders and nonresponders. Diabetes Care 39: 808‐815, 2016.
 442.Steven S, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B, Al‐Mrabeh A, Daly AK, Batterham RL, Taylor R. Weight loss decreases excess pancreatic triacylglycerol specifically in type 2 diabetes. Diabetes Care 39: 158‐165, 2016.
 443.Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Muller M, van den Berg WB, van Rooijen N, Wabitsch M, Kullberg BJ, van der Meer JW, Kanneganti T, Tack CJ, Netea MG. The inflammasome‐mediated caspase‐1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 12: 593‐605, 2010.
 444.Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the danger zone. Cell Metab 15: 10‐18, 2012.
 445.Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: Role in diet‐induced obesity. Crit Rev Biochem Mol Biol 45: 199‐214, 2010.
 446.Stromsdorfer KL, Yamaguchi S, Yoon MJ, Moseley AC, Franczyk MP, Kelly SC, Qi N, Imai S, Yoshino J. NAMPT‐mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi‐organ insulin sensitivity in mice. Cell Rep 16: 1851‐1860, 2016.
 447.Succurro E, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Lauro R, Perticone F, Sesti G. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity (Silver Spring) 16: 1881‐1886, 2008.
 448.Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, Ogawa Y. Attenuation of obesity‐induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll‐like receptor 4 mutation. Biochem Biophys Res Commun 354: 45‐49, 2007.
 449.Summers SA, Garza LA, Zhou H, Birnbaum MJ. Regulation of insulin‐stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 18: 5457‐5464, 1998.
 450.Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet‐induced type II diabetes in C57BL/6J mice. Diabetes 37: 1163‐1167, 1988.
 451.Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6: 87‐102, 2008.
 452.Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakao K. Molecular cloning of rat leptin receptor isoform complementary DNAs–identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 225: 75‐83, 1996.
 453.Takeuchi K, Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. Am J Physiol 296: E1195‐E1209, 2009.
 454.Talukdar S, Oh DY, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M, Li P, Yan Q, Zhu Y, Ofrecio J, Lin M, Brenner MB, Olefsky JM. Neutrophils mediate insulin resistance in mice fed a high‐fat diet through secreted elastase. Nat Med 18: 1407‐1412, 2012.
 455.Tam CS, Covington JD, Bajpeyi S, Tchoukalova Y, Burk D, Johannsen DL, Zingaretti CM, Cinti S, Ravussin E. Weight gain reveals dramatic increases in skeletal muscle extracellular matrix remodeling. J Clin Endocrinol Metab 99: 1749‐1757, 2014.
 456.Tam CS, Covington JD, Ravussin E, Redman LM, Pennington CT. Little evidence of systemic and adipose tissue inflammation in overweight individuals(dagger). Front Genet 3: 58, 2012.
 457.Tam CS, Viardot A, Clement K, Tordjman J, Tonks K, Greenfield JR, Campbell LV, Samocha‐Bonet D, Heilbronn LK. Short‐term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes 59: 2164‐2170, 2010.
 458.Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, Ariyasu H, Akamizu T, Kita T, Yokode M, Arai H. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 28: 2195‐2201, 2008.
 459.Tataranni PA, Ortega E. A burning question: Does an adipokine‐induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 54: 917‐927, 2005.
 460.Tateya S, Kim F, Tamori Y. Recent advances in obesity‐induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 4: 93, 2013.
 461.Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: The personal fat threshold. Clin Sci (Lond) 128: 405‐410, 2015.
 462.Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, Khosla S, Jensen MD, Kirkland JL. Fat tissue, aging, and cellular senescence. Aging Cell 9: 667‐684, 2010.
 463.Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, Kirkland JL. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 17: 644‐656, 2013.
 464.Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, Zhao X, Sarruf DA, Izgur V, Maravilla KR, Nguyen HT, Fischer JD, Matsen ME, Wisse BE, Morton GJ, Horvath TL, Baskin DG, Tschop MH, Schwartz MW. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 122: 153‐162, 2012.
 465.Thorpe KE, Florence CS, Howard DH, Joski P. The impact of obesity on rising medical spending. Health Aff (Millwood) Suppl Web Exclusives: W4‐480‐6, 2004.
 466.Thorpe LE, Upadhyay UD, Chamany S, Garg R, Mandel‐Ricci J, Kellerman S, Berger DK, Frieden TR, Gwynn C. Prevalence and control of diabetes and impaired fasting glucose in New York City. Diabetes Care 32: 57‐62, 2009.
 467.Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6: 772‐783, 2006.
 468.Trachta P, Dostalova I, Haluzikova D, Kasalicky M, Kavalkova P, Drapalova J, Urbanova M, Lacinova Z, Mraz M, Haluzik M. Laparoscopic sleeve gastrectomy ameliorates mRNA expression of inflammation‐related genes in subcutaneous adipose tissue but not in peripheral monocytes of obese patients. Mol Cell Endocrinol 383: 96‐102, 2014.
 469.Trak‐Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high‐calorie diet. Int J Exp Pathol 92: 413‐421, 2011.
 470.Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 7: 410‐420, 2008.
 471.Travers RL, Motta AC, Betts JA, Bouloumie A, Thompson D. The impact of adiposity on adipose tissue‐resident lymphocyte activation in humans. Int J Obes (Lond) 39: 762‐769, 2015.
 472.Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: A basis for the dysregulation of tissue function in obesity? Br J Nutr 100: 227‐235, 2008.
 473.Trayhurn P, Wood IS. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92: 347‐355, 2004.
 474.Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA, Katsilambros N. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 48: 1332‐1335, 1999.
 475.Turer AT, Scherer PE. Adiponectin: Mechanistic insights and clinical implications. Diabetologia 55: 2319‐2326, 2012.
 476.Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Bronneke HS, Trifunovic A, LoSasso G, Wunderlich FT, Kornfeld JW, Bluher M, Kronke M, Bruning JC. Obesity‐induced CerS6‐dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 20: 678‐686, 2014.
 477.Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287: 664‐666, 2000.
 478.Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF‐alpha‐mediated insulin resistance in genetic obesity. Endocrinology 139: 4832‐4838, 1998.
 479.Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity‐induced insulin resistance in mice lacking TNF‐alpha function. Nature 389: 610‐614, 1997.
 480.Vague J. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 4: 20‐34, 1956.
 481.Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS. A predominant role for parenchymal c‐Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 3: e3151, 2008.
 482.van Beek L, Lips MA, Visser A, Pijl H, Ioan‐Facsinay A, Toes R, Berends FJ, Willems van Dijk K, Koning F, van Harmelen V. Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. Metabolism 63: 492‐501, 2014.
 483.van Dielen FM, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor‐1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab 89: 4062‐4068, 2004.
 484.Van Ginderachter JA, Meerschaut S, Liu Y, Brys L, De Groeve K, Hassanzadeh Ghassabeh G, Raes G, De Baetselier P. Peroxisome proliferator‐activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 108: 525‐535, 2006.
 485.van Vliet‐Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, Gaye A, Gogele M, Heier M, Hiekkalinna T, Joensuu A, Newby C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege HL, Holmen J, Jula A, Kootstra‐Ros JE, Kvaloy K, Holmen TL, Mannisto S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: A collaborative analysis of ten large cohort studies. BMC Endocr Disord 14: 9, 2014.
 486.Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity‐induced inflammation and insulin resistance. Nat Med 17: 179‐188, 2011.
 487.Vasiliauskaite‐Brooks I, Sounier R, Rochaix P, Bellot G, Fortier M, Hoh F, De Colibus L, Bechara C, Saied EM, Arenz C, Leyrat C, Granier S. Structural insights into adiponectin receptors suggest ceramidase activity. Nature 544: 120‐123, 2017.
 488.Vazquez LA, Pazos F, Berrazueta JR, Fernandez‐Escalante C, Garcia‐Unzueta MT, Freijanes J, Amado JA. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 90: 316‐322, 2005.
 489.Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: Relationships in obesity. Obesity Res 12: 962‐971, 2004.
 490.Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M, Kollias G, Moller DE. Targeted disruption of the tumor necrosis factor‐alpha gene: Metabolic consequences in obese and nonobese mice. Diabetes 46: 1526‐1531, 1997.
 491.Viana EC, Araujo‐Dasilio KL, Miguel GP, Bressan J, Lemos EM, Moyses MR, de Abreu GR, de Azevedo JL, Carvalho PS, Passos‐Bueno MR, Errera FI, Bissoli NS. Gastric bypass and sleeve gastrectomy: The same impact on IL‐6 and TNF‐alpha. Prospective clinical trial. Obes Surg 23: 1252‐1261, 2013.
 492.Viardot A, Lord RV, Samaras K. The effects of weight loss and gastric banding on the innate and adaptive immune system in type 2 diabetes, prediabetes. J Clin Endocrinol Metab 95: 2845‐2850, 2010.
 493.Vicennati V, Vottero A, Friedman C, Papanicolaou DA. Hormonal regulation of interleukin‐6 production in human adipocytes. Int J Obes Relat Metab Disord 26: 905‐911, 2002.
 494.Vieira‐Potter VJ. Inflammation and macrophage modulation in adipose tissues. Cell Microbiol 16: 1484‐1492, 2014.
 495.Viguerie N, Vidal H, Arner P, Holst C, Verdich C, Avizou S, Astrup A, Saris WH, Macdonald IA, Klimcakova E, Clement K, Martinez A, Hoffstedt J, Sorensen TI, Langin D. Adipose tissue gene expression in obese subjects during low‐fat and high‐fat hypocaloric diets. Diabetologia 48: 123‐131, 2005.
 496.Villaret A, Galitzky J, Decaunes P, Esteve D, Marques MA, Sengenes C, Chiotasso P, Tchkonia T, Lafontan M, Kirkland JL, Bouloumie A. Adipose tissue endothelial cells from obese human subjects: Differences among depots in angiogenic, metabolic, and inflammatory gene expression and cellular senescence. Diabetes 59: 2755‐2763, 2010.
 497.Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C‐reactive protein levels in overweight and obese adults. JAMA 282: 2131‐2135, 1999.
 498.Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 21: 697‐738, 2000.
 499.Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 529: 326‐335, 2016.
 500.Wang Q, Dong Z, Liu X, Song X, Song Q, Shang Q, Jiang Y, Guo C, Zhang L. Programmed cell death‐4 deficiency prevents diet‐induced obesity, adipose tissue inflammation, and insulin resistance. Diabetes 62: 4132‐4143, 2013.
 501.Warden CH, Fisler JS. Comparisons of diets used in animal models of high‐fat feeding. Cell Metab 7: 277, 2008.
 502.Watanabe Y, Nakamura T, Ishikawa S, Fujisaka S, Usui I, Tsuneyama K, Ichihara Y, Wada T, Hirata Y, Suganami T, Izaki H, Akira S, Miyake K, Kanayama HO, Shimabukuro M, Sata M, Sasaoka T, Ogawa Y, Tobe K, Takatsu K, Nagai Y. The radioprotective 105/MD‐1 complex contributes to diet‐induced obesity and adipose tissue inflammation. Diabetes 61: 1199‐1209, 2012.
 503.Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW, Jr. CCR2 modulates inflammatory and metabolic effects of high‐fat feeding. J Clin Invest 116: 115‐124, 2006.
 504.Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796‐1808, 2003.
 505.Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 115: 1111‐1119, 2005.
 506.Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP. Fatty acid‐induced NLRP3‐ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12: 408‐415, 2011.
 507.Wensveen FM, Valentic S, Sestan M, Turk Wensveen T, Polic B. The “Big Bang” in obese fat: Events initiating obesity‐induced adipose tissue inflammation. Eur J Immunol 45: 2446‐2456, 2015.
 508.Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, Wabitsch M, O'Brien PE, Harrison LC. Pro‐inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 59: 1648‐1656, 2010.
 509.West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine inbred mouse strains. Am J Physiol 262: R1025‐R1032, 1992.
 510.Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity, type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930‐1935, 2001.
 511.Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 17: 610‐617, 2011.
 512.Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM. Normalization of obesity‐associated insulin resistance through immunotherapy. Nat Med 15: 921‐929, 2009.
 513.Withrow D, Alter DA. The economic burden of obesity worldwide: A systematic review of the direct costs of obesity. Obesity Rev 12: 131‐141, 2011.
 514.Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti‐inflammatory cytokines IL‐10, IL‐1RA in human leukocytes. Biochem Biophys Res Commun 323: 630‐635, 2004.
 515.Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J, Chu WC, Chan HL. Fatty pancreas, insulin resistance, and beta‐cell function: A population study using fat‐water magnetic resonance imaging. Am J Gastroenterol 109: 589‐597, 2014.
 516.Wu D, Molofsky AB, Liang HE, Ricardo‐Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332: 243‐247, 2011.
 517.Wu D, Ren Z, Pae M, Han SN, Meydani SN. Diet‐induced obesity has a differential effect on adipose tissue and macrophage inflammatory responses of young and old mice. Biofactors 39: 326‐333, 2013.
 518.Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, Sweeney JF, Peterson LE, Chan L, Smith CW, Ballantyne CM. T‐cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115: 1029‐1038, 2007.
 519.Wu L, Parekh VV, Gabriel CL, Bracy DP, Marks‐Shulman PA, Tamboli RA, Kim S, Mendez‐Fernandez YV, Besra GS, Lomenick JP, Williams B, Wasserman DH, Van Kaer L. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc Natl Acad Sci U S A 109: E1143‐E1152, 2012.
 520.Wueest S, Rapold RA, Schumann DM, Rytka JM, Schildknecht A, Nov O, Chervonsky AV, Rudich A, Schoenle EJ, Donath MY, Konrad D. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest 120: 191‐202, 2010.
 521.Xia B, Cai GH, Yang H, Wang SP, Mitchell GA, Wu JW. Adipose tissue deficiency of hormone‐sensitive lipase causes fatty liver in mice. PLoS Genet 13: e1007110, 2017.
 522.Xia JY, Holland WL, Kusminski CM, Sun K, Sharma AX, Pearson MJ, Sifuentes AJ, McDonald JG, Gordillo R, Scherer PE. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab 22: 266‐278, 2015.
 523.Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity‐related insulin resistance. J Clin Invest 112: 1821‐1830, 2003.
 524.Xu J, Yeh CH, Chen S, He L, Sensi SL, Canzoniero LM, Choi DW, Hsu CY. Involvement of de novo ceramide biosynthesis in tumor necrosis factor‐alpha/cycloheximide‐induced cerebral endothelial cell death. J Biol Chem 273: 16521‐16526, 1998.
 525.Xu M, Palmer AK, Ding H, Weivoda MM, Pirtskhalava T, White TA, Sepe A, Johnson KO, Stout MB, Giorgadze N, Jensen MD, LeBrasseur NK, Tchkonia T, Kirkland JL. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife 4: e12997, 2015.
 526.Xu X, Grijalva A, Skowronski A, van Eijk M, Serlie MJ, Ferrante AW, Jr. Obesity activates a program of lysosomal‐dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab 18: 816‐830, 2013.
 527.Xu XJ, Apovian C, Hess D, Carmine B, Saha A, Ruderman N. Improved insulin sensitivity 3 months after RYGB surgery is associated with increased subcutaneous adipose tissue AMPK activity and decreased oxidative stress. Diabetes 64: 3155‐3159, 2015.
 528.Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino‐Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL. Transcriptome‐based network analysis reveals a spectrum model of human macrophage activation. Immunity 40: 274‐288, 2014.
 529.Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon‐Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656‐660, 2007.
 530.Yamauchi T, Iwabu M, Okada‐Iwabu M, Kadowaki T. Adiponectin receptors: A review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 28: 15‐23, 2014.
 531.Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty‐acid oxidation by activating AMP‐activated protein kinase. Nat Med 8: 1288‐1295, 2002.
 532.Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama‐Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat‐derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941‐946, 2001.
 533.Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada‐Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13: 332‐339, 2007.
 534.Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, Snitker S, Horenstein RB, Hull K, Goldberg NH, Goldberg AP, Shuldiner AR, Fried SK, Gong DW. Acute‐phase serum amyloid A: An inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3: e287, 2006.
 535.Yazdani‐Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC. Relapse of diabetes after interruption of chronic administration of anti‐tumor necrosis factor‐alpha antibody infliximab: A case observation. Diabetes Care 29: 1712‐1713, 2006.
 536.Yazdani‐Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, Graninger W, Wascher TC. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti‐TNF‐alpha antibody infliximab. Eur J Clin Invest 34: 641‐642, 2004.
 537.Yazdi FT, Clee SM, Meyre D. Obesity genetics in mouse and human: Back, forth, and back again. Peer J 3: e856, 2015.
 538.Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol 293: E1118‐E1128, 2007.
 539.Yin MJ, Yamamoto Y, Gaynor RB. The anti‐inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase‐beta. Nature 396: 77‐80, 1998.
 540.Yin X, Lanza IR, Swain JM, Sarr MG, Nair KS, Jensen MD. Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size. J Clin Endocrinol Metab 99: E209‐E216, 2014.
 541.Yki‐Jarvinen H, Sammalkorpi K, Koivisto VA, Nikkila EA. Severity, duration, and mechanisms of insulin resistance during acute infections. J Clin Endocrinol Metab 69: 317‐323, 1989.
 542.Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C‐reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972‐978, 1999.
 543.Zamarron BF, Mergian TA, Cho KW, Martinez‐Santibanez G, Luan D, Singer K, DelProposto JL, Geletka LM, Muir LA, Lumeng CN. Macrophage proliferation sustains adipose tissue inflammation in formerly obese mice. Diabetes 66: 392‐406, 2017.
 544.Zeiser R. Immune modulatory effects of statins. Immunology 154: 69‐75, 2018.
 545.Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ, Stulnig TM. Human adipose tissue macrophages are of an anti‐inflammatory phenotype but capable of excessive pro‐inflammatory mediator production. Int J Obes (Lond) 31: 1420‐1428, 2007.
 546.Zeyda M, Huber J, Prager G, Stulnig TM. Inflammation correlates with markers of T‐cell subsets including regulatory T cells in adipose tissue from obese patients. Obesity (Silver Spring) 19: 743‐748, 2011.
 547.Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett 112: 61‐67, 2007.
 548.Zhang J, Liu F. Tissue‐specific insulin signaling in the regulation of metabolism, aging. IUBMB Life 66: 485‐495, 2014.
 549.Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425‐432, 1994.
 550.Zheng Y, Eilertsen KJ, Ge L, Zhang L, Sundberg JP, Prouty SM, Stenn KS, Parimoo S. Scd1 is expressed in sebaceous glands, and is disrupted in the asebia mouse. Nat Genet 23: 268‐270, 1999.
 551.Zhou L, Park SY, Xu L, Xia X, Ye J, Su L, Jeong KH, Hur JH, Oh H, Tamori Y, Zingaretti CM, Cinti S, Argente J, Yu M, Wu L, Ju S, Guan F, Yang H, Choi CS, Savage DB, Li P. Insulin resistance and white adipose tissue inflammation are uncoupled in energetically challenged Fsp27‐deficient mice. Nat Commun 6: 5949, 2015.
 552.Zhu X, Zong G, Zhu L, Jiang Y, Ma K, Zhang H, Zhang Y, Bai H, Yang Q, Ben J, Li X, Xu Y, Chen Q. Deletion of class A scavenger receptor deteriorates obesity‐induced insulin resistance in adipose tissue. Diabetes 63: 562‐577, 2014.
 553.Zoico E, Garbin U, Olioso D, Mazzali G, Fratta Pasini AM, Di Francesco V, Sepe A, Cominacini L, Zamboni M. The effects of adiponectin on interleukin‐6 and MCP‐1 secretion in lipopolysaccharide‐treated 3T3‐L1 adipocytes: Role of the NF‐kappaB pathway. Int J Mol Med 24: 847‐851, 2009.
 554.Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat “fatty.” Endocrinology 90: 1320‐1330, 1972.
 555.Zucker TF, Zucker LM. Fat accretion and growth in the rat. J Nutr 80: 6‐19, 1963.

 

Teaching Material

M. S. Burhans, D. K. Hagman, J. N. Kuzma, K. A. Schmidt, M. Kratz. Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus. Compr Physiol 9: 2019, 1-58.

Didactic Synopsis

Major Teaching Points:

  • Low-grade chronic inflammation includes the accumulation of proinflammatory macrophages and other immune cells in adipose tissue, and their secretion of mediators of inflammation such as tumor necrosis factor α and interleukins 1β and 6.
  • Low-grade chronic adipose tissue inflammation is strongly and consistently associated with excess body fat mass in mouse models of obesity as well as overweight and obese humans.
  • Adipose tissue inflammation is also consistently associated with systemic insulin resistance, a major determinant of glucose intolerance, and genetic alterations that reduce adipose tissue inflammation are very consistently associated with improved insulin sensitivity.
  • Rare exceptions in which adipose tissue inflammation and insulin resistance are not associated with one another illustrate that other factors contribute to the etiology of insulin resistance as well. These include lipid accumulation and inflammation in other metabolically active tissues such as the liver.

Didactic Legends

The figures—in a freely downloadable PowerPoint format—can be found on the Images tab along with the formal legends published in the article. The following legends to the same figures are written to be useful for teaching.

Figure 1 Associations between obesity, insulin resistance, and adipose tissue inflammation.Teaching points: Obesity is associated with both insulin resistance and adipose tissue inflammation in humans and animal models. Adipose tissue inflammation and insulin resistance are also associated, but the direction of causality is controversial.

Figure 2 Causes of and health risks associated with obesity. Teaching points: The development of obesity is complex and many factors are known to contribute to it; these factors may have an environmental, biological, or genetic basis. Obesity increases the risk for the development of many other diseases and disorders, including CVD, T2DM, and cancer, three of the top ten killers of adults in the United States.

SES, socioeconomic status; PCOS, polycystic ovary syndrome; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus; NAFLD, nonalcoholic fatty liver disease; GERD, gastroesophageal reflux disease.

Figure 3 Insulin sensitivity, pancreatic β-cell function, and glucose effectiveness in the regulation of glucose homeostasis.Teaching points: Glucose tolerance is the body's ability to maintain glucose within a relatively narrow homeostatic range and is regulated by three key factors: insulin sensitivity, pancreatic β-cell function, and glucose effectiveness (A) (38, 215, 420). Insulin sensitivity is the responsiveness of target cells to insulin signaling (215). In healthy, glucose tolerant individuals, a decline in insulin sensitivity is compensated for by an increase in insulin production and secretion (shown in green, normal glucose tolerance) (B) (217). Only when the pancreatic β-cells are unable to fully compensate for a decline in insulin sensitivity will glucose intolerance (shown in yellow, impaired glucose tolerance) and eventually T2DM (shown in red) ensue (217). Figure 3b reproduced from Kahn et al. (216), with permission.

Figure 4 Obesity is associated with the development of insulin resistance.Teaching points: The association between excess adiposity and insulin resistance is well established in humans and animal models. However, there are known exceptions to this relationship wherein some obese individuals may be insulin sensitive while some individuals with a deficit of adipose tissue, as in lipodystrophy, may be severely insulin resistant.

Figure 5 Variation in adiposity and insulin resistance among inbred strains of mice.Teaching points: This large-scale animal study very clearly showed that genetic variation has a major impact on both adiposity and insulin sensitivity in response to a high calorie diet. In this study, over 100 inbred mouse strains were fed a high-sugar high-fat diet for eight weeks and fat mass, percent body fat, and insulin resistance were measured. This study design allowed the authors to assess the effect of genetics on these metabolic phenotypes. The substantial variability in adiposity and insulin sensitivity across the different mouse strains in response to the high-sugar high-fat diet is evident and indicates that genetic variation exerts significant control over these phenotypes. These results also support the idea that total adiposity may not be the primary factor driving the development of insulin resistance. Reproduced from Parks et al. (371), with permission.

Figure 6 Insulin sensitivity and adiposity are negatively associated in humans.Teaching points: In this study, the authors used the euglycemic hyperinsulinemic clamp procedure to measure the glucose infusion rate (y-axis) needed to maintain glucose concentrations in plasma constant under high insulin concentrations, which is the gold-standard method for the determination of insulin sensitivity. A high glucose infusion rate is indicative of high insulin sensitivity. In nonobese to obese individuals (body mass index, BMI, on the x-axis), they found that adiposity and insulin sensitivity are negatively correlated. In addition, this study also highlights the variability in insulin sensitivity that exists at any given BMI, indicating that total fat mass is not the only determinant of insulin sensitivity. Indeed, there are obese individuals who maintain a level of insulin sensitivity equivalent to those with a non-obese BMI. These individuals may be referred to as “metabolically healthy obese (MHO)” and are estimated to comprise approximately 10% to 30% of the obese population. These individuals do not develop metabolic syndrome, insulin resistance, and impaired glucose tolerance that would be expected based on their BMI. Figure reproduced with permission. Reproduced, with permission, from Kloeting et al. (238).

Figure 7 Type 2 diabetes is an aging-associated disease.Teaching points: The prevalence of diabetes increases with age and is nearly doubled in the 65 and older population as compared to the 45- to 64-year-old population (65). Aging is also associated with insulin resistance that may be largely explained by a shift in adiposity from subcutaneous to visceral depots and an increase in ectopic fat accumulation.

Figure 8 Metabolic characterization of obesity, metabolically healthy obesity (MHO), and lipodystrophy.Teaching points: The study of obesity, metabolically healthy obesity (MHO), and lipodystrophy reveals that healthy, functional adipose tissue may be a key determinant of overall metabolic health. Although all obese individuals are characterized by excess fat tissue, not all obese individuals develop metabolic dysfunction such as insulin resistance. A small proportion of the obese population maintains a state of metabolic health in which they remain more insulin sensitive as compared to metabolically unhealthy obese individuals (44, 45). Lipodystrophy, on the other hand, is characterized by a reduced amount of adipose tissue, but is usually accompanied by ectopic fat deposition and severe insulin resistance (140). These examples strongly suggest that total adiposity is not likely the primary determinant of metabolic health.

Figure 9 Adipose tissue inflammation may be a driving factor in the development of systemic insulin resistance (IR).Teaching points: Chronic, low-grade adipose tissue inflammation is associated with the development of systemic IR in obesity. There are several potential mechanisms through which adipose tissue inflammation may contribute to the development of IR, including an increase in the production and secretion of proinflammatory cytokines that directly contributes to systemic inflammation and impairs adipocyte insulin sensitivity. IR at the level of the adipocyte results in increased lipolysis and secretion of free fatty acids. Adipose tissue inflammation is also associated with reduced secretion of the insulin-sensitizing adipokine adiponectin. Reduced adiponectin and increased pro-inflammatory cytokine signaling may lead to increased levels of ceramides, which are also associated with adipose tissue inflammation and insulin resistance. Many of these mechanisms also contribute to the development of ectopic fat accumulation, in organs such as the liver and skeletal muscle, which is also strongly associated with systemic IR.

Figure 10 Obesity is associated with adipose tissue inflammation.Teaching points: The development of chronic, low-grade adipose tissue inflammation is common in obesity.

Figure 11 Insulin resistance and adipose tissue inflammation are strongly associated.Teaching points: Although insulin resistance and adipose tissue inflammation generally characterize obese adipose tissue, the direction of causality has not been conclusively determined.

Figure 12 Key functions of immune cells in adipose tissue physiology.Teaching points: Although obesity is associated with the development of chronic, low-grade adipose tissue inflammation, the immune cells that infiltrate the adipose tissue perform several different functions that allow for healthy expansion of adipose tissue during chronic caloric excess. Examples of functions of macrophages in adipose tissue include the breakdown of extracellular matrix proteins as cells expand and to create room for new adipocytes, and laying down new extracellular matrix, processes that are collectively known as “tissue remodeling” (A). Macrophages also play a critical role in the formation of new blood vessels as the tissue expands, that is, angiogenesis (B). The activation of inflammatory pathways in adipocytes and immune cells (C) also may play an important physiological role because the induction of insulin resistance in adipocytes (D) may serve to limit excessive hypertrophy of these cells, which is known to trigger cell death. Macrophages are also able to intermittently store lipid (E), which could become important whenever the lipid-storage capacity of adipocytes is (temporarily) restricted. And lastly, macrophages play a key role in the removal of cellular debris from necrotic or apoptotic adipocytes or senescent cells (F).

Figure 13 Adipose tissue inflammation, ectopic fat deposition, and insulin resistance in obesity.Teaching points: During chronic caloric excess, a major challenge for adipose tissue is to store the excess calories as triglycerides. This requires the adipose tissue to expand, either by increasing the number of adipocytes (hyperplasia) or by increasing the size of existing adipocytes (hypertrophy). Currently available evidence suggests that the ability of adipose tissue, particularly subcutaneous adipose tissue, to expand in a healthy fashion is reliant primarily upon hyperplasia. An increase in the number of functional lipid-storing adipocytes prevents excessive adipocyte hypertrophy. This is one key differentiating factor between obese individuals that remain relatively insulin sensitive (upper panel) from those that become insulin resistant (lower panel). Larger adipocytes are more susceptible to cell death and are more strongly associated with immune cell infiltration, activation of pro-inflammatory pathways, and a state of insulin resistance. Inflammation and insulin resistance in adipose tissue are major contributors to low-grade chronic systemic inflammation, low adiponectin concentrations in the circulation, and an elevated flux of adipose tissue-derived free fatty acids (FFA) to organs such as liver, muscle, and pancreas. Accumulation of triglycerides in liver and muscle are considered a major contributor to insulin resistance in these organs, and triglycerides stored in the pancreas may impair the inability of the β-cell to fully compensate for insulin resistance. The importance of adipose tissue inflammation in driving systemic insulin resistance relative to the other, interlinked factors outlined here is currently unclear, particularly in humans.

 


Related Articles:

Impact of Growth Hormone on Regulation of Adipose Tissue
Endocrine Function after Bariatric Surgery
Circadian Rhythms in Adipose Tissue Physiology
Contribution of Maladaptive Adipose Tissue Expansion to Development of Cardiovascular Disease
Energy storage
Contribution of Adipose Tissue to Development of Cancer

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus
 

How to Cite

Maggie S. Burhans, Derek K. Hagman, Jessica N. Kuzma, Kelsey A. Schmidt, Mario Kratz. Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus. Compr Physiol 2018, 9: 1-58. doi: 10.1002/cphy.c170040